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Abstract: 
GSK3082 – a hepatitis C virus RNA polymerase inhibitor – and a series of analogues with structural 
diversity  at  the  5-position  were  prepared  from  a  2,2,4,5-tetrasubstituted  pyrrolidine  obtained  with  a 
well-defined stereochemistry from the 1,3-dipolar cycloaddition of the chiral imino ester derived from 
leucine  tert-butyl  ester  and  (R)-2,3-O-isopropylideneglyceraldehyde  with  methyl  acrylate.  The  chiral 
2,2-dimethyl-1,3-dioxolane moiety provided by the glyceraldehyde served as a synthetic equivalent for 
different substituents and functional groups and these transformations usually required mild reaction 
conditions and simple work-up procedures. The inhibitory activity of the resulting GSK3082 analogues 
was studied in vitro in a cell-based assay of the subgenomic HCV RNA replication system. Some of 
the analogues showed good inhibitory activity with IC50 values in the nanomolar concentration range.  
Key  words:  Hepatitis  C  virus  (HCV), N-Acylpyrrolidines,  HCV  replication  inhibitors,  Structure-
Activity relationshiphs 
1. Introduction 
Hepatitis C virus (HCV) is a biological pathogenic agent and it is considered to be the most common 
cause of chronic liver disease worldwide [1]. The progressive destruction and regeneration of the liver 
parenchyma  caused  by  chronic  liver  disease  is  associated  with  the  development  of  fibrosis,  liver 
cirrhosis, hepatocellular carcinoma and eventually liver failure and death [2].  HCV infection 
constitutes a major public health problem: a large number of people – about 325 million worldwide in 
2015 – are carriers of hepatitis B or C virus infections, each year 1.75 million people newly acquire 
hepatitis C virus infection and in 2015 alone viral hepatitis caused 1.34 million deaths, most of which 
were due to chronic liver disease and primary liver cancer [3]. 
Inhibition of HCV NS5B polymerase, a key enzyme for HVC replication with RNA-dependent RNA 
polymerase  function  [4],  has  proven  to  be  a  goal  of  paramount  importance  for  the  development  of 
specifically targeted antiviral therapy for HCV [5]. The potent antiviral effect of polymerase inhibitors 
has led to the development of nucleos(t)ide and non-nucleoside analogues for the treatment of chronic 
hepatitis C patients [6]. 
 
 
 
 
 
 
 
 
 
Figure 1. General structure of N-acylpyrrolidines identified as of HCV NS5B polymerase inhibitors. 
In the above context, N-acylpyrrolidines with the general structure A (Figure 1) have been identified as 
reversible, non-competitive inhibitors of HCV NS5B polymerase [7]. Structural analyses have shown
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that  compounds  from  the  N-acylpyrrolidine  series  bind  in  the  palm  pocket  I  of
active site of the polymerase [6h,8]. 
Optimization of the structure based on the analysis of structure-activity relationships (Glaxo-
SmithKline)  led  to  the  identification  of  GSK3082  [7c],  a  potent  inhibitor  of  RNA-dependent  RNA 
polymerase (NS5B) in enzymatic assays that also inhibits viral RNA replication in cell-based replicon 
assays. These SAR studies showed that (i) the presence of a bulky non-polar group in the 2-position 
increases  activity,  (ii)  aryl  groups  with  lipophilic  electron-withdrawing  groups  in  the  acyl  moiety 
enhance  activity,  with  the  4-(tert-butyl)-3-methoxybenzoyl  group  being  optimal,  and  (iii)  that  the 
substituent at the 5-position can be widely varied. 
1,3-Dipolar cycloaddition has proven to be a flexible and versatile synthetic strategy to gain access to 
the pyrrolidine core of biologically active compounds [8]. Previously described non-stereoselective [7], 
diastereoselective  [9]  and  enantioselective  [10]  syntheses  of  antiviral  compounds  with  the  general 
structure A have been performed using 1,3-dipolar cycloaddition of iminoglycinates and acrylates as 
the key step. Substituents R 1 and R 3 are provided by the amino acid and the aldehyde from which the 
iminoglycinate is obtained and substituent R 2 is generated from the carboxylate moiety in the acrylate 
(Scheme 1).  
 
 
 
 
 
 
Scheme 1. Strategy for synthesis of N-acylpyrrolidines. 
One of our research goals is the synthesis of versatile chiral intermediates from imines derived from 
glyceraldehyde – which is readily accessible from inexpensive D-mannitol – and the development of 
synthetic  routes  to  obtain  bioactive  compounds  in  enantiomerically  pure  form  from  these  chiral 
intermediates [11]. With this aim in mind, we studied the behaviour of chiral iminoesters derived from 
glyceraldehyde  acetonide  in  azomethine  ylide  cycloadditions  and  developed  a  stereoselective  and 
flexible  methodology  for  the  synthesis  of  2,2,4,5-tetrasubstituted  pyrrolidines  with  a  well-defined 
stereochemistry [12]. We presume that this methodology would be amenable to the synthesis of HCV 
NS5B polymerase inhibitors and related structural analogues. In the work reported here, we synthesised 
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a series of novel N-acylpyrrolidines – in which the substituent at 5-position in GSK3082 was varied – 
starting from a common precursor. The target compounds are potential HCV polymerase inhibitors and 
their inhibitory activities were evaluated in vitro in a cell-based assay of the subgenomic HCV RNA 
replication system.  
 
2. Results and discussion 
2.1. Chemistry 
Based  on  our  previous  experience  we  envisaged  that  the  pyrrolidine  core  of  structural  analogues  of 
GSK3082 with different substituents in the 5-position could be obtained by the 1,3-dipolar 
cycloaddition  between  an  acrylate  and  an  iminoester  derived  from D-glyceraldehyde  acetonide  and 
leucine using silver acetate for metallation. In this way the 2,2,4,5-tetrasubstituted pyrrolidine with the 
appropriate configuration would be obtained. The chiral 2,2-dimethyl-1,3-dioxolane moiety provided 
by the glyceraldehyde has a double role: (i) to control the stereochemical course of the reaction and (ii) 
to serve as a synthetic equivalent for different substituents and functional groups (Scheme 2). The tert-
butylimino ester 1 and methyl acrylate were selected as reagents to obtain an orthogonally protected 
pyrrolidine. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Strategy for synthesis GSK3082 analogues. 
Starting  imino  ester  1  was  prepared  by  reaction  of  (S)-leucine  tert-butyl  ester  with  (R)-2,3-O-
isopropylideneglyceraldehyde  in  ether  at  room  temperature  for  2  h  in  the  presence  of  anhydrous 
MgSO4  as  a  dehydrating  agent.  The  crude  imino  ester  was  directly  submitted  to  a  1,3-dipolar 
cycloaddition reaction with methyl acrylate without any purification. Reaction using silver acetate (20 
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mol%) as the catalyst and DBU (20 mol%) as the base in toluene at room temperature for 24 h led to an 
85/15 mixture of endo adducts 2a/2b in 95% yield, in which compound 2a with the desired (2S,4S,5R) 
configuration was in excess. The absolute configuration of the major endo adduct was unambiguously 
established by a single-crystal X-ray diffraction study on compound 4a, which was obtained from 2a as 
shown  below.  Acylation  of  the  mixture  with  4-(tert-butyl)-3-methoxybenzoyl  chloride  provided  the 
corresponding  N-acyl  pyrrolidines  3a/3b  as  an  85/15  mixture  of  diastereoisomers  in  96%  yield 
(Scheme 3). 
 
Scheme 3. Synthesis of N-acylpyrrolidine 3a. 
The synthesis of GSK3082 was completed as shown in Schemes 4 and 5. Reduction of the methyl ester 
was  achieved  with  a  combination  of  NaBH4-MeOH  (1:2)  in  the  presence  of  a  catalytic  amount  of 
NaB(OAc)3H  (2.5  mol  %  relative  to  NaBH4)  [10a].  After  stirring  3a/3b  in  THF  for  4  days  at  room 
temperature the corresponding 4-hydroxymethylpyrrolidines were obtained as an 85/15 diastereomeric 
mixture, from which 4a and 4b were isolated as diastereomerically pure compounds in 81% and 12% 
yield, respectively.  
The O-methylation of 4a with an excess of methyl iodide in the presence of potassium tert-butoxide in 
THF at room temperature was complete after 18 h and provided compound 5 in 88% yield. The 2,2-
dimethyl-1,3-dioxolane  moiety  was  converted  into  the  required  thiazol-2-yl  substituent  at  the  5-
position  by  first  converting  the  acetonide  5  into  the  aldehyde  7.  Chemoselective  deprotection  using 
BiCl3 in dry acetonitrile provided diol 6 in 81% yield [13] and this was subsequently converted into the 
aldehyde 7 in 94% yield by oxidation with sodium periodate.  
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 Scheme 4. The synthetic route for key intermediate 7. 
Further  oxidation  of  aldehyde  7  with  potassium  permanganate  using  a  mixture  of  tert-butanol  and 
aqueous NaH2PO4 as the reaction medium [14], followed by treatment with of isopropyl chloroformate 
in  the  presence  of  N-methylmorpholine  in  THF  at  room  temperature  and  subsequent  reaction  with 
ammonium  hydroxide  gave  a  79%  yield  of  formamide  8.  Direct  conversion  of  formamide  8  into 
thioamide 10 using Lawesson’s reagent was unsuccessful and we evaluated a two-step procedure using 
nitrile  9  as  the  intermediate.  Reaction  of  formamide  8  with  POCl3  in  pyridine  [15]  provided  a  51% 
yield of the nitrile intermediate 9, which was subsequently converted into thioamide 10 (95% yield) by 
the action of 40–44% aqueous ammonium sulfide solution in methanol. At this point we evaluated the 
direct conversion of aldehyde 7 to nitrile 9. This transformation was successfully achieved in 99% yield 
using  iodine  in  ammonia  water  [16].  In  an  effort  to  prevent  epimerization,  the  final  thiazol-2-yl 
substituent  at  the  5-position  in  GSK3082  was  prepared  via  a  modified  Hantzsch  method  [15]  that 
involved the cyclocondensation of thioamide 10 with bromoacetaldehyde in dry dimethoxyethane using 
NaHCO3 as base followed by dehydratation of the hydroxythiazoline intermediate by treatment with 
trifluoroacetic anhydride–pyridine. In this way compound 11 was obtained in 87% yield with complete 
stereocontrol. Finally, hydrolysis of the tert-butyl ester with trifluoroacetic acid in dichloromethane at 0 
ºC yielded GSK3082 in 95% yield. GSK3082 was obtained from 1 in 10 steps with a good overall yield 
of 38%. 
 
THF, rt
NaBH4-MeOH (1:2)
NaB(OAc)3H (cat)
3a 3b
+
NtBuO2C
CO2Me
ArCO
H
O
O NtBuO2CH2
CO2Me
ArCO
H
O
O
dr 85/15 NtBuO2C
H
O
O
NtBuO2C
ArCO
H
O
O
ArCO
4b (12%)
4a (81%)
Ar = 3-MeO-4-tBuC6H3-
MeI/KOtBu
THF, 0 ºC
88%
NtBuO2C
H
O
O
ArCO
5
BiCl3
MeCN, rt
81%
NtBuO2C
H
OH
OH
ArCO
6
NaIO4
THF-H2O, 35 ºC
94%
NtBuO2C
H
CHO
ArCO
7
OH
OH
OMe OMe OMe
 Scheme 5. The synthetic route for target compound GSK3082. 
Cyclocondensation of thioamide 10 with ethyl bromopyruvate using this protocol led to an 88% yield 
of compound 12, which upon hydrolysis with trifluoroacetic acid in dichloromethane at 0 ºC afforded 
GSK3082 analogue 13 in 95% yield without detectable epimerization (Scheme 6).  
 
 
 
 
 
 
 
 
 
Scheme 6. The synthetic route for GSK3082 analogue 13. 
Alternatively, the thiazol-2-yl substituent at the 5-position was installed by reaction of thioamide 10 
with α-bromoacetaldehyde diethyl acetal in THF under reflux and in the presence of a catalytic amount 
of HCl in dioxane [17]. In this way compound 14 – the epimer of 11 at C5 – was obtained in 51% 
yield, again with complete stereocontrol. tert-Butyl ester 14 was readily hydrolysed to the 
corresponding acid 15 in 96% yield under the same conditions as above (Scheme 7). 
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Scheme 7. The synthetic route for GSK3082 analogue 15. 
The  synthesis  of  the  first  set  of  structural  analogues  of  GSK3082  with  substituents  with  different 
structural  characteristics  in  the  5-position  was  readily  achieved  from  intermediates  5,  6  and  8  as 
detailed  below.  The  chemoselective  hydrolysis  of  the  tert-butyl  ester  compound  5  was  carried  out 
under reflux with a methanolic solution of potassium hydroxide and this gave analogue 16 in nearly 
quantitative yield. Compound 6 was reacted with 1,1'-carbonyldiimidazole in THF at 60 ºC to produce 
carbonate 17 in 90% yield, which upon hydrolysis with trifluoroacetic acid in dichloromethane at 0 ºC 
led to analogue 18 in 94% yield. GSK3082 analogue 19 was obtained in 96% yield by treatment of 
amide 8 with trifluoroacetic acid in dichloromethane at 0 ºC (Scheme 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 8. The synthetic route for GSK3082 analogues 16, 18 and 19. 
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Other GSK3082 analogues were obtained from versatile chiral intermediate 7 by transformation of the 
formyl group into methoxymethyl, ethyl and methoxycarbonyl groups, as shown in Scheme 9. Reaction 
of compound 7 with sodium borohydride in ethanol reduced the C5 formyl group to a hydroxymethyl 
group, which in turn reacted with methyl iodide to give compound 20 in 85% yield over the two steps. 
Subsequent  hydrolysis  of  20  with  trifluoroacetic  acid  in  dichloromethane  at  0  ºC  gave  GSK3082 
analogue 21 in 98% yield. Synthesis of analogue 23 involved oxidation of the formyl group, which was 
performed  with  potassium  permanganate  using  a  mixture  of  tert-butanol  and  aqueous  NaH2PO4  as  a 
reaction medium as above. The resulting carboxylic acid was immediately converted into its methyl 
ester using trimethylsilyldiazomethane. Transformation of aldehyde 7 into methyl ester 22 took place to 
give 89% yield over the two steps and final hydrolysis with trifluoroacetic acid in dichloromethane at 0 
ºC afforded a 97% yield of analogue 23. Wittig reaction of 7 and the unstabilised ylide derived from 
triphenylphosphonium methyl bromide gave olefin 24 in 91% yield. Compound 24 was hydrogenated 
to  25  (93%)  with  molecular  hydrogen  using  Pd/C  as  the  catalyst.  Hydrolysis  of  the  tert-butyl  ester 
under the usual acidic conditions afforded analogue 26 in 97% yield. 
 
Scheme 9. The synthetic route for GSK3082 analogues 21, 23 and 26. 
Compounds  13,  15,  16,  18,  19,  21,  23  and  26  were  tested  as  inhibitors  by  mimicking  HCV  viral 
replication in cells using a subgenomic HCV RNA replication system and, on the basis of their in vitro 
activity (see below), we prepared a second set of structural analogues of GSK3082 taking into account 
the  beneficial  effect  of  the  presence  of  a  heteromethyl  side  chain  at  C5.  Firstly,  aldehyde  7  was 
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efficiently converted into acetate 27, allyl ether 29 or methylcarbonate 31 by reduction 7 with sodium 
borohydride in ethanol followed by the immediate dimethylaminopyridine-catalysed acetylation with 
acetic  anhydride,  reaction  with  allyl  bromide  in  the  presence  of  sodium  hydride  or  treatment  with 
methyl  chloroformate  in  the  presence  of  a  catalytic  amount  of  dimethylaminopyridine.  Subsequent 
hydrolysis of these compounds with trifluoroacetic acid in dichloromethane at 0 ºC yielded GSK3082 
analogues 28, 30 and 32 in 94–95% yields from starting aldehyde 7 (Scheme 10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 10. The synthetic route for GSK3082 analogues 28, 30 and 32. 
Compound  7  was  also  converted  into  GSK3082  analogues  34,  36  and  38  with  a  fluoromethyl, 
azidomethyl or acetylaminometyl side chain at C5 (Scheme 11). Access to the fluoromethyl side chain 
was  achieved  by  sequential  treatment  of  aldehyde  7  with  sodium  borohydride  in  ethanol  and  the 
fluorinating agent diethylaminosulfur trifluoride (DAST). Compound 33, obtained in 52% yield, was 
hydrolysed  with  trifluoroacetic  acid  in  dichloromethane  at  0  ºC  to  afford  analogue  34  in  almost 
quantitative  yield.  The  intermediate  hydroxymethyl  derivative  obtained  in  the  reduction  of  7  with 
sodium  borohydride  in  ethanol  was  immediately  reacted  first  with  methanesulfonyl  chloride  in  the 
presence of triethylamine and then with sodium azide in the presence of a catalytic amount of sodium 
iodide to afford 35. Hydrolysis of this compound under the usual conditions gave analogue 36 in 95% 
from aldehyde 7. Catalytic reduction of azide 35 gave the corresponding amine, which was 
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immediately  acetylated  with  acetic  anhydride-triethylamine  to  produce  acetylamino  derivative  37  in 
65% yield. Subsequent hydrolysis with trifluoroacetic acid in dichloromethane at 0 ºC yielded analogue 
38 in 95% yield. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 11. The synthetic route for GSK3082 analogues 34, 36 and 38. 
2.2. Biological evaluation 
In  order  to  evaluate  the  potency  and  cytotoxicity  of  the  14  synthesised  compounds,  viral  replication 
was assessed by in vitro HCV replication assays with genotype 1b Con1 HCV subgenomic replicons 
(Huh 5-2) [18] and the results were compared to those obtained for GSK3082. All of the compounds 
inhibited  HCV  replicon  replication  (measured  as  the  luciferase  signal)  in  a  dose-dependent  manner, 
with EC50 values lower than 100 microM (Table 1, Figure 2). The estimated EC50 values for these 
compounds  ranged  from  nanomolar  to  micromolar.  The  anti-HCV  activity  was  not  the  result  of  a 
cytostatic effect [19], since the CC50 values for these compounds were significantly higher than the 
EC50 values. 
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Table 1. Evaluation of the potency and cytotoxicity of the obtained compounds in cell assays  
Compound R EC50a (M) CC50b (M) 
GSK3082  0.1 >120 
13  60 200 
15           * 15 200 
16  60 >120 
18  2 >120 
19 CONH2 2 >120 
21 CH2OMe 0.6 >120 
23 CO2Me 7 >120 
26 Et 40 200 
28 CH2OAc 30 >120 
30 CH2OAllyl 7.5 >120 
32 CH2OMoc 30 >120 
34 CH2F 45 >120 
36 CH2N3 100 >120 
38 CH2NHAc 15 >120 
aEC50,  effective  concentration  50%; bCC50,  cytotoxic  concentration  50%.  Relative  error  in  the 
parameters is 15%.  
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Figure 2. Evaluation of viral load reduction (bars) of the HCV replicon system in human hepatoma 
cells  (Huh5-2)  with  cell  growth  (lines)  upon  increasing  the  concentration  of  compound  GSK3082 
(green) and 21 (red).*UTC: untreated controls. 
2.3. SAR analysis 
To uncover relationships between EC50 activities and structural features or physical-chemical 
properties  in  the  compound  series,  a  simple  SAR  (Structure-Activity  Relationship)  analysis  was 
performed.  The  compound  structures  were  optimized  and  36  molecular  descriptors  were  calculated. 
Then,  we  sought  for  linear  correlations  between  effectiveness  of  compounds  against  HCV  NS5B 
polymerase  (-log(EC50))  and  any  of  the  previously  calculated  molecular  descriptors.  Although  this 
analysis did not show any high correlation between any of the molecular descriptors selected and the 
biological activity (not shown) it provided some clues. It was noticed that GSK3082, the most effective 
compound, presented marked differences with most other compounds in regard to properties such as 
aromatic  ratio  (ARR)  and  reactivity  (Re)  (Figure  3  panels  A  and  B).  According  to  these  plots,  only 
compounds  15  and  13  differentiated  from  the  group  in  the  same  direction  as  GSK3082.  This  was 
somewhat expected due to their close structural similarity (15 is a GSK3082's estereoisomer and 13 
presents the same thiazole ring but ramified with an ethyl carboxylate) but did not allow us to explain 
their  lower  activity  compared  to  that  of  GSK3082.  On  the  other  hand,  compound  13  was  that  with 
highest  molecular  weight  (Figure  3  panel  C)  and  displayed  one  of  the  lowest  activities.  Thus,  we 
thought the activity could be qualitatively correlated with structural features of the complexes formed 
by the compounds and the target enzyme. Based on the availability of a 3D structure for the complex 
between HCV NS5B polymerase and a ligand structurally close to GSK3082 (PDB code: 2jc1) [7c], 
we  modeled  the  binding  of  all  the  compounds.  As  shown  in  SI  Figure  S1  (panels  B  and  C)  both 
compounds 15 and 13 appear to face steric problems (clashes) to fit in the putative binding site. As for 
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the remaining compounds, the lower activity of 16, 23, 28, 30, 32 and 38 could also be related to steric 
issues (SI Figure S2 panel A), while that of the others (e.g. 18, 19, 21, 26, 34 and 36, SI Figure S2 
panel  B)  appears  related  to  loss  of  polar  and/or  hydrophobic  interactions  with  the  protein  binding 
pocket. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.  Scatter  plots  of  molecular  descriptor  values  versus  the  assayed  biological  activities:  (A) 
aromatic ratio, (B) reactivity and (C) molecular weight values versus the effectiveness of compounds 
against HCV NS5B polymerase. Substituent structures (R 3) at the 5-position in compounds GSK3082, 
13 and 15 are shown. 
3. Conclusions 
In summary, we have developed a very efficient diastereoselective approach to novel 2,2,4,5-
tetrasubstituted N-acyl pyrrolidines with a well-defined stereochemistry starting from a chiral 
iminoester  derived  from  leucine  tert-butyl  ester  and  (R)-2,3-O-isopropylideneglyceraldehyde.  The 
cycloadduct derived from the 1,3-dipolar cycloaddition with methyl acrylate has served as a common 
precursor for the synthesis of GSK3082 and structurally related compounds with different substituents 
at C5, with the chiral 2,2-dimethyl-1,3-dioxolane moiety provided by the glyceraldehyde acting as a 
synthetic equivalent for structural diversity. The inhibitory activity of the obtained GSK3082 analogues 
has been studied in vitro in a cell-based assay of a subgenomic HCV RNA replication system and some 
of  the  analogues  have  shown  a  good  inhibitory  activity  with  estimated  IC50  values  ranging  from 
nanomolar to micromolar. 
 
4. Experimental Section 
4.1. Chemistry 
4.1.1. General Details 
Unless  otherwise  specified,  all  reagents  were  obtained  from  commercial  suppliers  and  were  used  as 
received without further purification. For anhydrous conditions, reactions were carried out under Ar in 
solvents dried using a Solvent Purification System (SPS). TLC was performed on precoated silica gel 
60  F254  polyester  plates  and  products  were  visualised  using  UV  light  (254  nm)  and  potassium 
permanganate solutions followed by heating. Column chromatography was performed on silica gel (60, 
40−63  μm)  with  air  pressure.  Melting  points  were  determined  in  open  capillary  tubes  and  are  not 
corrected. FT-IR spectra were recorded as thin films on NaCl plates, νmax values expressed in cm –1 are 
given for the main absorption bands. Optical rotations were measured on a digital polarimeter at λ 589 
nm  and  25  ºC  in  cells  with  1  or  10  cm  path  length,  [α]D  values  are  given  in  10–1  deg·cm2·g–1  and 
concentrations  are  given  in  g/100  mL. 1H, 19F  and 13C  NMR  spectra  were  acquired  on  a  400  MHz 
spectrometer in the stated deuterated solvent at room temperature unless otherwise stated using a 5-mm 
probe. 13C NMR spectra were acquired with the 1H broad-band decoupled mode, chemical shifts (δ) are 
reported  in  parts  per  million  (ppm)  with  the  solvent  resonance  as  the  internal  standard  [20],  and 
coupling  constants  (J)  in  hertz  (Hz).  High-resolution  mass  spectra  were  recorded  from  methanolic 
solutions on a MICROTOF-Q (quadrupole time-of-flight) micro instrument using the positive 
electrospray ionization mode (ESI+). The X-ray diffraction data were collected at room temperature on 
a four-circle diffractometer, using graphite-monochromated Mo-Ka radiation (l = 0.71073 Å). 
 4.1.2. Synthesis of crude (E)-tert-butyl N-{[(S)-2,2-dimethyl-1,3-dioxolan-4-yl]methylidene}-(S)-
leucinate (1) 
To a solution of (S)-leucine tert-butyl ester hydrochloride (1,79 g, 8.0 mmol) in water (5 mL) at room 
temperature was added a solution of potassium carbonate (2.21 g, 16.0 mmol) in water (5 mL). The 
resulting solution was extracted with dichloromethane (3 x 20 mL) and the combined organic layers 
were dried over anhydrous MgSO 4, filtered and evaporated under reduced pressure to give crude tert-
butyl  (S)-leucinate.  In  the  meantime  to  a  stirred  solution  of  1,2:5,6-di-O-isopropylidene-D-mannitol 
(1.31  g,  5.0  mmol)  in  dichloromethane  (20  mL)  at  room  temperature  was  added  saturated  aqueous 
solution of sodium hydrogen carbonate (1 mL). Then, sodium metaperiodate (2.14 g, 10.0 mmol) was 
added with vigorous agitation and the reaction was allowed to proceed for 1 h at 35 ºC. The solids were 
removed by filtration and washed with dichloromethane (30 mL). The combined organic solutions were 
dried over anhydrous MgSO4, filtered and evaporated under reduced pressure at less than 30 ºC to give 
crude (R)-2,3-O-isopropylideneglyceraldehyde, which was used immediately in the condensation 
reaction with tert-butyl (S)-leucinate. To a solution containing crude tert-butyl (S)-leucinate and (R)-
2,3-O-isopropylideneglyceraldehyde  in  dry  diethyl  ether  (20  mL)  at  room  temperature  was  added 
anhydrous MgSO4 (1.0 g) and the resulting suspension was stirred for 2 h. The reaction mixture was 
then  filtered  and  the  solid  residue  was  washed  with  diethyl  ether  (20  mL).  The  combined  organic 
filtrates were evaporated under reduced pressure to afford 2.60 g of crude imine 2 of 65 % purity, as 
determined by 1H NMR using 1,3,5-trimethoxybenzene as an internal standard [21]. Crude imine 2 was 
used without further purification in the next reaction. Oil; 1H NMR (400 MHz, CDCl 3) δ 0.85 (d, J = 
6.6  Hz,  3H),  0.92  (d,  J  =  6.6  Hz,  3H),  1.39  (s,  3H),  1.41−1.43  (m,  1H),  1.44  (s,  3H),  1.45  (s,  9H), 
1.63−1.99 (m, 2H), 3.78 (dd, J = 8.2, 6.2 Hz, 1H), 3.94 (dd, J = 8.5, 5.9 Hz, 1H), 4.20 (dd, J = 8.5, 6.9 
Hz, 1H), 4.65 (ddd, J = 6.9, 5.9, 4.7 Hz, 1H), 7.66 (d, J = 4.7 Hz, 1H).  
 
4.1.3.  2-(tert-Butyl)  4-methyl  (2S,4S,5R)-5-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-isobutylpyrrolidine-
2,4-dicarboxylate (2a) 
To a stirred suspension of crude imine 1 of 65% purity (2.60 g, 5.6 mmol) and silver acetate (183 mg, 
1.1  mmol)  in  dry  toluene  (30  mL)  under  argon  at  room  temperature  were  sequentially  added  ethyl 
acrylate (966 mg, 11.2 mmol) and DBU (171 mg, 1.1 mmol), both of them previously solved in dry 
toluene (1 mL). The reaction mixture was stirred in the dark at room temperature for 24 h. The mixture 
was  quenched  with  water  (5  mL)  and  filtered  through  a  short  Celite® pad.  Celite®  residues  were 
thoroughly  washed  with  diethyl  ether  (50  mL)  and  the  combined  organic  filtrates  were  dried  over 
anhydrous  MgSO4,  filtered  and  concentrated  under  reduced  pressure.  The  crude  cycloadducts  were 
purified by flash chromatography (eluent: diethyl ether/hexane, 1/2) to afford 2 (2.05 g, 95% yield) as a 
mixture of endo diasteroisomers 2a and 2b (2a/2b = 85/15). Some column chromatography fractions 
containing exclusively major cycloadduct 2a were used for characterization purposes. Colourless oil; 
[α]D24 = −39.23 (c = 1.11 in CHCl 3); IR (neat) 3341, 3308, 1734 cm –1; 1H NMR (400 MHz, CDCl 3) δ 
0.83 (d, J = 6.4 Hz, 3H), 0.90 (d, J = 6.5 Hz, 3H), 1.29 (s, 3H), 1.39 (s, 3H), 1.41−1.45 (m, 1H), 1.46 
(s, 9H), 1.61−1.74 (m, 2H), 1.81 (dd, J = 13.7, 7.9 Hz, 1H), 2.48 (dd, J = 13.7, 5.5 Hz, 1H), 2.92 (ddd, 
J = 7.9, 6.9, 5.5 Hz, 1H), 3.00 (bs, 1H), 3.26 (dd, J = 6.9, 5.3 Hz, 1H), 3.60 (s, 3H), 3.71 (dd, J = 8.0, 
7.1 Hz, 1H), 3.93 (dd, J = 8.0, 6.4 Hz, 1H), 4.12−4.20 (m, 1H); 13C-APT{1H} NMR (100 MHz, CDCl3) 
δ 23.7, 24.4, 25.5, 25.5, 26.6, 28.0, 40.9, 46.2, 49.2, 51.8, 63.2, 67.5, 68.7, 75.0, 81.1, 109.3, 173.5, 
175.1; HRMS(ESI+) m/z [M+H]+ calcd for C20H36NO6 386.2538, found 386.2546. 
 
4.1.4.  2-(tert-Butyl)  4-methyl  (2S,4S,5R)-1-(4-(tert-butyl)-3-methoxybenzoyl)-5-((S)-2,2-dimethyl-1,3-
dioxolan-4-yl)-2-isobutylpyrrolidine-2,4-dicarboxylate (3a) 
A mixture of 4-tert-butyl-3-methoxybenzoic acid (1.56 g, 7.5 mmol) and thionyl chloride (12 mL) was 
refluxed for 4 hours. Thionyl choride in excess was removed by evaporation under reduced pressure 
and  the  residue  was  solved  in  toluene  (5  mL).  The  organic  solvent  was  evaporated  under  reduced 
pressure to remove thionyl chloride traces and the crude 4-tert-butyl-3-methoxybenzoyl chloride was 
solved in anhydrous dichloromethane (10 mL). To this stirred solution at 0 ºC was added a solution of 
compound 2 as an 85/15 mixture of diastereoisomers 2a and 2b (1.93 g, 5.0 mmol) in dichloromethane 
(10  mL)  followed  by  triethylamine  (2.8  mL,  20.1  mmol)  and  this  mixture  was  stirred  at  room 
temperature for 36 hours. After that, the reaction mixture was washed with saturated aqueous sodium 
bicarbonate solution (2 x 20 mL). The organic layer was dried over MgSO 4, filtered and evaporated 
under reduced pressure. The residue was purified by flash chromatography (1st eluent: diethyl 
ether/hexane, 1/3; 2 nd eluent: diethyl ether/hexane 1/1) to afford 3 (2.76 g, 96% yield) as a mixture of 
endo diastereoisomers 3a and 3b (3a/3b = 85/15). Following the same experimental procedure starting 
from major diastereoisomer 2a, diastereomerically pure compound 3a was obtained and fully 
characterised. Colourless oil; [ α]D24 = 0.65 (c = 1.94 in CHCl 3); IR (neat) 1734, 1636, 1567 cm –1; 1H 
NMR (400 MHz, CDCl3) δ 0.52 (s, 3H), 0.97 (d, J = 6.6 Hz, 3H), 1.00 (d, J = 6.6 Hz, 3H), 1.12 (s, 3H), 
1.32 (s, 9H), 1.52 (s, 9H), 1.72−1.83 (m, 1H), 2.00 (dd, J = 15.1, 4.4 Hz, 1H), 2.25 (dd, J = 13.4, 6.9 
Hz, 1H), 2.24−2.32 (m, 1H), 2.64 (dd, J = 13.4, 13.4 Hz, 1H), 3.28 (dd, J = 7.7, 7.7 Hz, 1H), 3.47 (ddd, 
J = 13.4, 7.3, 6.9 Hz, 1H), 3.67−3.73 (m, 1H); 3.71 (s, 3H), 3.84 (s, 3H), 4.32−4.42 (m, 1H), 4.73 (dd, 
J = 9.3, 7.3 Hz, 1H), 6.92 (dd, J = 7.9, 1.6 Hz, 1H), 7.04 (d, J = 1.6 Hz, 1H), 7.18 (d, J = 7.9 Hz, 1H); 
13C-APT{1H} NMR (100 MHz, CDCl3) δ 24.4, 24.7, 24.9, 25.3, 25.7, 28.2, 29.6, 35.0, 36.1, 41.6, 44.6, 
52.3, 55.1, 65.3, 66.4, 69.3, 75.2, 81.5, 108.6, 112.6, 118.5, 125.7, 137.0, 140.4, 158.8, 169.7, 170.8, 
172.8; HRMS(ESI+) m/z [M+H]+ calcd for C32H50NO8 576.3531, found 576.3518. 
 
4.1.5. tert-Butyl (2S,4S,5R)-1-(4-(tert-butyl)-3-methoxybenzoyl)-5-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-
4-(hydroxymethyl)-2-isobutylpyrrolidine-2-carboxylate (4a) 
To a stirred solution of compound 3 as an 85/15 mixture of diastereoisomers 3a and 3b (2.30 g, 4.0 
mmol) in dry THF (40 mL) were sequentially added NaBH 4 (606 mg, 16.0 mmol) and NaB(OAc) 3H 
(172 mg, 0.8 mmol).  To the white slurry under argon at 0 ºC dry methanol (1.3 mL, 32.1 mmol) was 
added and the mixture was stirred at room temperature for 4 days until complete disappearance of the 
starting material was observed by TLC. The resulting reaction mixture was quenched with saturated 
aqueous  NH4Cl  solution  (20  mL)  and  the  organic  solvents  were  evaporated  under  reduced  pressure. 
The aqueous layer was extracted with dichloromethane (3 x 20 mL) and the combined organic layers 
were  dried  over  anhydrous  MgSO4,  filtered  and  concentrated  under  reduced  pressure.  The  crude 
product was purified by flash chromatography (1 st eluent: diethyl ether/hexane, 1/1; 2 nd eluent: diethyl 
ether) to provide diastereomerically pure 4a (1.78 g, 81% yield) as a white solid. M.p. = 204 ºC; [ α]D24 
= −3.07 (c = 0.99 in CHCl 3); IR (nujol) 3379, 1730, 1593, 1563 cm –1; 1H NMR (400 MHz, CDCl 3) 
δ 0.73 (s, 3H), 0.97 (d, J = 6.6 Hz, 3H), 1.00 (d, J = 6.6 Hz, 3H), 1.11 (s, 3H), 1.32 (s, 9H) 1.50 (s, 9H), 
1.77−1.89 (m, 1H), 1.93 (dd, J = 12.9, 12.9 Hz, 1H), 2.01 (dd, J = 14.9, 4.4 Hz, 1H), 2.14 (dd, J = 12.9, 
6.8 Hz, 1H), 2.25 (dd, J = 14.9, 6.0 Hz, 1H), 2.68 (bs, 1H), 2.80−2.94 (m, 1H), 3.48−3.63 (m, 2H), 3.67 
(dd, J = 8.8, 8.8 Hz, 1H), 3.83 (s, 3H), 3.98 (dd, J = 8.8, 6.5 Hz, 1H), 4.14−4.23 (m, 1H), 4.61 (dd, J = 
7.5, 7.5 Hz, 1H), 6.93 (dd, J = 7.9, 1.7 Hz, 1H), 7.01 (d, J = 1.7 Hz, 1H), 7.18 (d, J = 7.9 Hz, 1H); 13C-
APT{1H} NMR (100 MHz, CDCl 3) δ 24.5, 24.9, 25.0, 25.7, 28.2, 29.7, 35.0, 37.1, 41.9, 43.4, 55.2, 
61.1,  63.9,  66.9,  69.7,  75.5,  81.2,  108.0,  112.0,  118.5,  125.9,  137.0,  140.3,  158.7,  170.0,  173.2; 
HRMS(ESI+) m/z [M+H]+ calcd for C31H50NO7 548.3582, found 548.3598. 
 
4.1.6. tert-Butyl (2S,4S,5R)-1-(4-(tert-butyl)-3-methoxybenzoyl)-5-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-
2-isobutyl-4-(methoxymethyl)pyrrolidine-2-carboxylate (5) 
To a stirred solution of compound 4a (1.64 g, 3.0 mmol) in dry THF (30 mL) under argon at 0 ºC was 
added KOtBu (673.3 mg, 6.0 mmol) and the mixture was stirred at room temperature for 15 min. Then, 
iodomethane  (0.94  mL,  15.1  mmol)  was  added  and  the  slurry  was  stirred  for  18  hours  at  room 
temperature.  The resulting reaction mixture was quenched with saturated aqueous NH 4Cl solution (20 
mL) and the organic solvent was evaporated under reduced pressure. The aqueous layer was extracted 
with dichloromethane (3 x 20 mL) and the combined organic layers were dried over anhydrous MgSO 4, 
filtered and concentrated under reduced pressure. The crude product was purified by flash 
chromatography (eluent:  diethyl ether/hexane: 1/1), to provide compound 5 (1.78 g, 88% yield) as a 
white solid. M.p. = 109 ºC; [ α]D24 = −13.72 (c = 1.45 in CHCl 3); IR (nujol) 1729, 1612 cm –1; 1H NMR 
(400 MHz, CDCl3) δ 0.54 (s, 3H), 0.96 (d, J = 6.6 Hz, 3H), 1.00 (d, J = 6.6 Hz, 3H), 1.15 (s, 3H), 1.32 
(s, 9H), 1.50 (s, 9H), 1.81−1.99 (m, 1H), 1.93−2.05 (m, 2H), 2.13 (dd, J = 12.8, 6.8 Hz, 1H), 2.28 (dd, 
J = 14.8, 6.5 Hz, 1H), 2.83−2.96 (m, 1H), 3.17 (dd, J = 9.7, 9.2 Hz, 1H), 3.30 (s, 3H), 3.34 (dd, J = 9.7, 
5.1 Hz, 1H), 3.58 (dd, J = 8.6, 7.4 Hz, 1H), 3.83 (s, 3H), 3.87 (dd, J = 8.6, 6.4 Hz, 1H), 4.26 (ddd, J = 
9.3, 7.4, 6.4 Hz, 1H), 4.55 (dd, J = 9.3, 6.9 Hz, 1H), 6.92 (dd, J = 8.0, 1.7 Hz, 1H), 7.06 (d, J = 1.7 Hz, 
1H), 7.15 (d, J = 8.0 Hz, 1H); 13C-APT{1H} NMR (100 MHz, CDCl 3) δ 24.4, 24.7, 25.0, 25.4, 25.7, 
28.2,  29.7,  34.9,  36.8,  40.9,  41.8,  55.1,  58.8,  65.2,  67.0,  69.2,  71.2,  75.3,  81.0,  108.1,  112.7,  118.8, 
125.6,  137.5,  140.1,  158.7,  170.1,  173.4;  HRMS(ESI+)  m/z  [M+H]+  calcd  for  C32H52NO7  562.3739, 
found 562.3751. 
 
4.1.7.  tert-Butyl  (2S,4S,5R)-1-(4-(tert-butyl)-3-methoxybenzoyl)-5-((S)-1,2-dihydroxyethyl)-2-isobutyl-
4-(methoxymethyl)pyrrolidine-2-carboxylate (6) 
Compound  5  (1.40  g,  2.5  mmol)  and  bismuth(III)  chloride  (79  mg,  0.25  mmol)  were  mixed  in  wet 
acetonitrile  (50  mL)  and  the  mixture  was  stirred  at  room  temperature  for  4  hours.    The  resulting 
reaction mixture was quenched with saturated aqueous sodium bicarbonate solution (20 mL) and the 
organic  solvent  was  evaporated  under  reduced  pressure.  The  aqueous  layer  was  extracted  with 
dichloromethane  (3  x  20  mL)  and  the  combined  organic  layers  were  dried  over  anhydrous  MgSO4, 
filtered and concentrated under reduced pressure. The crude product was purified by flash 
chromatography  chromatography  (1st  eluent:  diethyl  ether/hexane,  1/1;  2nd  eluent:  diethyl  ether)  to 
provide  compound  6  (1.06  g,  81%  yield)  as  colourless  oil.  [α]D24  =  −17.34  (c  =  0.88  in  CHCl3);  IR 
(nujol) 3579, 3411, 1737, 1699, 1639, 1566 cm –1; 1H NMR (400 MHz, CDCl 3) δ 0.99 (d, J = 6.6 Hz, 
3H), 1.03 (d, J = 6.6 Hz, 3H), 1.34 (s, 9H), 1.53 (s, 9H), 1.78−1.90 (m, 1H), 1.95 (dd, J = 14.8, 5.0 Hz, 
1H), 2.00 (dd, J = 13.0, 13.0 Hz, 1H), 2.20 (dd, J = 13.0, 6.9 Hz, 1H), 2.37 (dd, J = 14.8, 6.0 Hz, 1H), 
2.83−2.98 (m, 1H), 3.02−3.14 (m, 1H), 3.20−3.29 (m, 1H), 3.30 (s, 3H), 3.33−3.42 (m, 3H), 3.57−3.66 
(m, 1H), 3.83 (s, 3H), 4.36 (dd, J = 6.7, 6.7 Hz, 1H), 5.26 (d, J = 5.4 Hz, 1H), 6.93 (dd, J = 7.9, 1.7 Hz, 
1H), 7.04 (d, J = 1.7 Hz, 1H), 7.21 (d, J = 7.9 Hz, 1H);  13C-APT{1H} NMR (100 MHz, CDCl3) δ 24.5, 
25.1, 25.7, 28.1, 29.7, 35.0, 37.8, 41.6, 41.7, 55.3, 59.0, 62.0, 64.9, 70.0, 70.4, 70.8, 83.3, 112.1, 119.1, 
126.0, 136.2, 140.4, 158.6, 171.2, 176.6; HRMS(ESI +) m/z [M+Na]+ calcd for C 29H47NNaO7 544.3245, 
found 544.3256. 
 
4.1.8. tert-Butyl (2S,4S,5R)-1-(4-(tert-butyl)-3-methoxybenzoyl)-5-formyl-2-isobutyl-4-
(methoxymethyl)pyrrolidine-2-carboxylate (7) 
To  a  stirred  solution  of  compound  6  (1.04  g,  2.0  mmol)  in  THF  (30  mL)  at  room  temperature  was 
added  water  (6  mL)  followed  by  sodium  metaperiodate  (1.71  g,  8.0  mmol)  and  the  mixture  was 
vigorously  stirred  at  35  ºC  for  16  hours.    After  that,  the  solvents  were  evaporated  under  reduced 
pressure and the residue was partitioned between a mixture of dichloromethane (30 mL) and water (10 
mL). The aqueous layer was extracted with dichloromethane (20 mL) and the combined organic layers 
were  dried  over  anhydrous  MgSO4,  filtered  and  concentrated  under  reduced  pressure.  The  crude 
product was purified by flash chromatography (eluent: diethyl ether/hexane, 1/1) to afford compound 7 
(921 mg, 94% yield) as a white solid. M.p. = 175 ºC; [ α]D24 = −3.55 (c = 1.01 in CHCl 3); IR (nujol) 
2727, 1728, 1630, 1563 cm –1; 1H NMR (400 MHz, CDCl 3) δ 1.03 (d, J = 6.5 Hz, 6H), 1.32 (s, 9H), 
1.53 (s, 9H), 1.77−1.91 (m, 1H), 2.07 (dd, J = 14.9, 3.7 Hz, 1H), 2.17 (dd, J = 13.1, 7.6 Hz, 1H), 2.26 
(dd, J = 13.1, 13.1 Hz, 1H), 2.35 (dd, J = 14.9, 8.2 Hz, 1H), 2.88−2.99 (m, 1H), 3.19 (s, 3H), 3.24 (dd, 
J = 9.8, 4.8 Hz, 1H), 3.43 (dd, J = 9.8, 5.2 Hz, 1H), 3.80 (s, 3H), 4.38 (dd, J = 9.1, 3.7 Hz, 1H), 6.75 (d, 
J = 1.7 Hz, 1H), 6.77 (dd, J = 7.8, 1.7 Hz, 1H), 7.22 (d, J = 7.8 Hz, 1H), 9.67 (d, J = 3.7, 1H); 13C-
APT{1H} NMR (100 MHz, CDCl 3) δ 24.0, 24.7, 25.8, 28.1, 29.6, 35.1, 38.0, 41.8, 43.2, 55.1, 58.7, 
69.6, 70.2, 70.9, 81.7, 109.6, 117.9, 127.0, 135.0, 140.6, 158.8, 169.5, 172.7, 200.1; HRMS(ESI +) m/z 
[M+H]+ calcd for C28H44NO6 490.3164, found 490.3149. 
 
4.1.9. tert-Butyl (2S,4S,5R)-1-(4-(tert-butyl)-3-methoxybenzoyl)-5-carbamoyl-2-isobutyl-4-
(methoxymethyl)pyrrolidine -2-carboxylate (8) 
A solution of compound 7 (146.9 mg, 0.3 mmol) in tert-butanol (12 mL) was diluted with an aqueous 
1.25M  sodium  phosphate  buffer  (4  mL)  and  the  resulting  mixture  was  treated  with  an  aqueous  1M 
potassium permanganate solution (1.8 mL, 1.8 mmol) at room temperature and vigorously stirred for 2 
hours. Then, saturated aqueous sodium sulfite solution (4 mL) was added and the pH of the mixture 
was adjusted to 3 with 1M hydrochloric acid. The reaction mixture was extracted with dichloromethane 
(3 x 20 mL) and the combined organic extracts were dried over MgSO 4 and evaporated under reduced 
pressure to afford a residue containing the crude acid. To a stirred solution of the resulting crude acid 
and N-methylmorpholine (30.5 mg, 0.3 mmol) in anhydrous THF (10 mL) at room temperature was 
added  a  1M  solution  of  isopropyl  chloroformate  in  toluene  (0.45  mL,  0.45  mmol)  and  the  mixture 
stirred for 30 minutes. Then, 28% ammonium hydroxide solution (1 mL) was added and the reaction 
mixture  was  stirred  for  2  hours.  The  organic  solvent  was  removed  under  reduced  pressure  and  the 
resulting aqueous solution was extracted with dichloromethane  (3 x 20 mL). The combined organic 
extracts  were  dried  over  anhydrous  MgSO4,  filtered  and  evaporated  under  reduced  pressure.    The 
residue was purified by flash chromatography (eluent: diethyl ether/hexane, 1/1) to afford compound 8 
(119.5 mg, 79% yield) as colourless oil. [ α]D24 = 7.83 (c = 1.01 in CHCl 3); IR (neat) 3324, 3189, 1697, 
1650, 1563 cm–1; 1H NMR (400 MHz, CDCl3) δ 1.00 (d, J = 6.6 Hz, 3H), 1.02 (d, J = 6.7 Hz, 3H), 1.32 
(s, 9H), 1.55 (s, 9H), 1.76−1.88 (m, 1H), 2.02 (dd, J = 13.1, 13.1 Hz, 1H), 2.08−2.19 (m, 2H), 2.41 (dd, 
J = 13.1, 6.4 Hz, 1H), 2.82−2.99 (m, 1H), 3.14 (dd, J = 9.6, 8.4 Hz, 1H), 3.29 (s, 3H), 3.59 (dd, J = 9.6, 
4.9 Hz, 1H), 3.80 (s, 3H), 4.44 (d, J = 9.0 Hz, 1H), 5.58 (bs, 1H), 6.86 (d, J = 1.7 Hz, 1H), 6.89 (dd, J = 
7.9, 1.7 Hz, 1H), 7.22 (d, J = 7.9 Hz, 1H), 9.25 (bs, 1H); 13C-APT{1H} NMR (100 MHz, CDCl 3) δ 
24.3,  25.0,  25.7,  28.1,  29.6,  35.0,  39.0,  41.3,  41.7,  55.1,  59.2,  65.9,  71.4,  72.3,  83.6,  109.8,  118.1, 
126.8,  134.7,  140.4,  158.5,  169.8,  173.0,  175.8;  HRMS(ESI +)  m/z  [M+H]+  calcd  for  C28H45N2O6 
505.3273, found 505.3290. 
 
4.1.10. tert-Butyl (2S,4S,5R)-1-(4-(tert-butyl)-3-methoxybenzoyl)-5-cyano-2-isobutyl-4-
(methoxymethyl)pyrrolidine -2-carboxylate (9) 
Method A: Phosphorus oxychloride (192 mg, 1.25 mmol) was added to a stirred solution of compound 
8 (252 mg, 0.5 mmol) in pyridine (3 mL) at 0 ºC and the solution was stirred for 6 hours at the same 
temperature. The resulting solution was poured into ice, diluted with water (3 mL) and extracted with 
diethyl ether (3 x 10 mL). The combined organic extracts were dried over anhydrous MgSO 4, filtered 
and  evaporated  under  reduced  pressure.  The  residue  was  purified  by  flash  chromatography  (eluent: 
diethyl ether/hexane, 1/2) to yield compound 9 (124 mg, 51% yield) as colourless oil. 
Method  B:  Iodine  (1.27  g,  5.0  mmol)  was  added  to  a  stirred  solution  of  compound  7  (245  mg,  0.5 
mmol) in aqueous 28% ammonium hydroxide solution (20 mL) and THF (5 mL) at room temperature 
and the reaction mixture was stirred for 16 hours.  After that, the resulting dark mixture was treated 
with saturated aqueous sodium sulfite solution (5 mL), followed by extraction with dichloromethane (2 
x 20 mL). The combined organic extracts were dried over anhydrous MgSO 4, filtered and evaporated 
under reduced pressure.  The residue was purified by flash chromatography (eluent: diethyl 
ether/hexane, 1/2) to afford compound 9 (240.9 mg, 99% yield) as colourless oil. [ α]D24 = 32.95 (c = 
1.01 in CHCl3); IR (neat) 2250, 1734, 1657, 1565 cm –1; 1H NMR (400 MHz, CDCl 3) δ 0.98 (d, J = 6.6 
Hz, 3H), 1.01 (d, J = 6.6 Hz, 3H), 1.36 (s, 9H), 1.55 (s, 9H), 1.70−1.82 (m, 1H), 2.00 (dd, J = 13.1, 
13.1 Hz, 1H); 2.05 (dd, J = 15.0, 3.4 Hz, 1H), 2.20 (dd, J = 13.1, 6.5 Hz, 1H), 2.39 (dd, J = 15.0, 8.8 
Hz, 1H), 2.83−2.96 (m, 1H), 3.33 (s, 3H), 3.47 (dd, J = 9.6, 9.6 Hz, 1H), 3.58 (dd, J = 9.6, 5.0 Hz, 1H), 
3.86 (s, 3H), 4.76 (d, J = 7.2 Hz, 1H), 6.92 (dd, J = 7.9, 1.7 Hz, 1H), 6.97 (d, J = 1.7 Hz, 1H), 7.30 (d, J 
= 7.9 Hz, 1H); 13C-APT{1H} NMR (100 MHz, CDCl 3) δ 23.5, 24.4, 25.7, 28.1, 29.6, 35.1, 37.4, 41.2, 
41.7, 55.1, 55.1, 59.4, 70.2, 72.0, 82.4, 109.3, 116.1, 117.3, 127.1, 134.7, 140.5, 158.7, 169.4, 171.9; 
HRMS(ESI+) m/z [M+H]+ calcd for C28H43N2O5 487.3167, found 487.3171. 
 
4.1.11. tert-Butyl (2S,4S,5R)-1-(4-(tert-butyl)-3-methoxybenzoyl)-5-carbamothioyl-2-isobutyl-4-
(methoxymethyl)pyrrolidine -2-carboxylate (10) 
Compound 9 (195.7 mg, 0.4 mmol) was solved in methanol (6 mL) and aqueous 40-44% ammonium 
sulfide solution (3 mL) was added. The reaction mixture was stirred at 90 ºC for 4 days in an autoclave. 
The  resulting  mixture  was  concentrated  under  reduced  pressure  and  the  residue  was  partitioned 
between dichloromethane (20 mL) and water (20 mL). The aqueous layer was further extracted with 
dichloromethane (2 x 20 mL) and the combined organic extracts were dried over anhydrous MgSO 4, 
filtered  and  evaporated  under  reduced  pressure.    The  residue  was  purified  by  flash  chromatography 
(eluent: diethyl ether/hexane, 1/2) to yield compound 10 (197.9 mg, 95% yield) as a white solid. M.p. = 
158 ºC; [α]D24 = −27.95 (c = 1.25 in CHCl 3); IR (nujol) 3302, 3138, 1743, 1700, 1653, 1565, 1500 cm –
1; 1H NMR (400 MHz, CDCl 3) δ 1.00 (d, J = 6.6 Hz, 3H), 1.01 (d, J = 6.6 Hz, 3H), 1.32 (s, 9H), 1.55 
(s, 9H), 1.75−1.90 (m, 1H), 1.99 (dd, J = 13.2, 13.2 Hz, 1H), 2.11 (d, J = 5.7 Hz, 2H), 2.42 (dd, J = 
13.2, 6.4 Hz, 1H), 2.85−2.98 (m, 1H), 3.12 (dd, J = 9.5, 9.2 Hz, 1H), 3.28 (s, 3H), 3.74 (dd, J = 9.5, 4.6 
Hz, 1H), 3.81 (s, 3H), 5.06 (d, J = 9.1 Hz, 1H), 6.79 (d, J = 1.7 Hz, 1H), 6.85 (dd, J = 7.9, 1.7 Hz, 1H), 
7.21 (d, J = 8.0 Hz, 1H), 7.62 (bs, 1H), 10.66 (bs, 1H); 13C-APT{1H} NMR (100 MHz, CDCl 3) δ 24.3, 
25.0,  25.7,  28.0,  29.6,  35.0,  39.0,  41.2,  41.6,  55.2,  59.1,  70.9,  72.3,  72.8,  83.9,  109.9,  118.2,  126.7, 
134.2, 140.4, 158.5, 170.0, 176.6, 205.2; HRMS(ESI +) m/z [M+H] + calcd for C 28H45N2O5S 521.3044, 
found 521.3058. 
 
4.1.12. tert-Butyl (2S,4S,5R)-1-(4-(tert-butyl)-3-methoxybenzoyl)-2-isobutyl-4-(methoxymethyl)-5-
(thiazol-2-yl)pyrrolidine -2-carboxylate (11) 
To a solution of thioamide 10 (52.1 mg, 0.1 mmol) and crude bromoacetaldehyde with a 21.5 % purity 
[22]  (228.7  mg,  0.4  mmol)  in  dry  dimethoxyethane  (2  mL)  was  added  sodium  hydrogen  carbonate 
(67.2  mg,  0,8  mmol)  and  the  mixture  was  stirred  at  room  temperature  for  18  hours.  The  reaction 
mixture was concentrated under reduced pressure and the residue was partitioned between 
dichloromethane (10 mL) and water (10 mL). The aqueous layer was further extracted with 
dichloromethane (2 x 10 mL) and the combined organic extracts were dried over anhydrous MgSO 4, 
filtered and evaporated under reduced pressure.  The residue was solved in dry dimethoxiethane (1mL) 
and cooled to 0 ºC. A solution of trifluoroacetic anhydride (84.1 mg, 0,4 mmol) in dry 
dimethoxyetnane (0.5 mL) was added followed by a solution of pyridine (63.3 mg, 0.8 mmol) in dry 
dimethoxyetane  (0.5  mL).  The  reaction  mixture  was  stirred  at  room  temperature  for  24  hours.  After 
that,  the  resulting  mixture  was  concentrated  under  reduced  pressure  and  the  residue  was  partitioned 
between dichloromethane (20 mL) and water (10 mL). The aqueous layer was further extracted with 
dichloromethane (2 x 10 mL) and the combined organic extracts were dried over anhydrous MgSO 4, 
filtered  and  evaporated  under  reduced  pressure.  The  residue  was  purified  by  flash  chromatography 
(eluent: diethyl ether/hexane, 1/1) to afford compound 11 (47.4 mg, 87% yield) as a brown solid. M.p. 
= 144 ºC; [α]D24 = 66.42 (c = 0.55 in CHCl 3); IR (neat) 3113, 1713, 1608, 1567, 1502 cm –1;  1H NMR 
(400 MHz, CDCl 3) δ 1.06 (d, J = 6.6 Hz, 3H), 1.07 (d, J = 6.6 Hz, 3H), 1.27 (s, 9H), 1.58 (s, 9H), 
1.91−2.02 (m, 1H), 2.10 (dd, J = 14.6, 7.0 Hz, 1H), 2.25−2.35 (m, 3H), 2.81 (dd, J = 9.4, 7.1 Hz, 1H), 
2.95 (dd, J = 9.4, 6.6 Hz, 1H), 3.02−3.14 (m, 1H), 3.06 (s, 3H), 3.55 (s, 3H), 5.46 (d, J = 8.5 Hz, 1H), 
6.31 (d, J = 1.7 Hz, 1H), 6.62 (dd, J = 7.9, 1.7 Hz, 1H), 7.09 (d, J = 7.9 Hz, 1H), 7.19 (d, J = 3.2 Hz, 
1H), 7.48 (d, J = 3.2 Hz, 1H); 13C-APT{1H} NMR (100 MHz, CDCl 3) δ 24.6, 25.3, 25.6, 28.3, 29.6, 
34.9, 37.3, 42.7, 42.8, 54.8, 59.0, 63.9, 70.9, 72.0, 81.9, 109.4, 117.1, 119.8, 126.4, 135.9, 139.2, 141.7, 
158.3, 169.5, 169.8, 172.2; HRMS(ESI+) m/z [M+H]+ calcd for C30H45N2O5S 545.3044, found 
545.3061. 
 
4.1.13. (2S,4S,5R)-1-(4-(tert-Butyl)-3-methoxybenzoyl)-2-isobutyl-4-(methoxymethyl)-5-(thiazol-2-
yl)pyrrolidine -2-carboxylic acid (GSK3082) 
To a solution of compound 11 (27.2 mg, 0.05 mmol) in dichloromethane (0.6 mL) at 0 ºC was added 
trifluoroacetic acid (0.2 mL) and the resulting solution was stirred at 0 ºC for 14 hours. The reaction 
mixture  was  diluted  with  dichloromethane  (15  mL),  neutralised  with  saturated  aqueous  sodium 
hydrogen carbonate solution and carefully acidified at pH 1 with 1M hydrochloric acid. The organic 
layer  was  separated  and  the  aqueous  layer  was  extracted  with  dichloromethane  (2  x  10  mL).  The 
combined  organic  extracts  washed  with  water  (10  mL),  dried  over  anhydrous  MgSO4,  filtered  and 
evaporated  under  reduced  pressure  to  give  compound  1  (23.1  mg,  95%  yield)  as  a  brown  solid.  All 
physical and spectroscopic data are in agreement with those previously described in the literature.7c 
 
4.1.14.  tert-Butyl  (2S,4S,5R)-1-(4-(tert-butyl)-3-methoxybenzoyl)-5-(4-(ethoxycarbonyl)thiazol-2-yl)-2-
isobutyl-4-(methoxymethyl)pyrrolidine -2-carboxylate (12) 
To a solution of thioamide 10 (52.1 mg, 0.1 mmol) and ethyl bromopyruvate 85% (91.8 mg, 0.4 mmol) 
in dry dimethoxyethane (2 mL) was added sodium hydrogen carbonate (67.2 mg, 0,8 mmol) and the 
mixture  was  stirred  at  room  temperature  for  18  hours.  The  reaction  mixture  was  concentrated  under 
reduced pressure and the residue was partitioned between dichloromethane (10 mL) and water (10 mL). 
The aqueous layer was further extracted with dichlorometane (2 x 10 mL) and the combined organic 
extracts  were  dried  over  anhydrous  MgSO4,  filtered  and  evaporated  under  reduced  pressure.    The 
residue was solved in dry dimethoxyethane (1 mL) and cooled to 0 ºC. A solution of trifluoroacetic 
anhydride (84.1 mg, 0,4 mmol) in dry dimethoxyetnane (0.5 mL) was added followed by a solution of 
pyridine  (63.3  mg,  0.8  mmol)  in  dry  dimethoxyetane  (0.5  mL).  The  reaction  mixture  was  stirred  at 
room  temperature  for  24  hours.  After  that,  the  resulting  mixture  was  concentrated  under  reduced 
pressure and the residue was partitioned between dichloromethane (20 mL) and water (10 mL). The 
aqueous  layer  was  further  extracted  with  dichlorometane  (2  x  10  mL)  and  the  combined  organic 
extracts  were  dried  over  anhydrous  MgSO4,  filtered  and  evaporated  under  reduced  pressure.  The 
residue was purified by flash chromatography (eluent: diethyl ether/hexane, 1/1) to afford compound 
12 (54.2 mg, 88% yield) as a brown solid. M.p. = 114 ºC; [α]D24 = 53.75 (c = 1.05 in CHCl3); IR (nujol) 
3092, 1730, 1653, 1591 cm–1; 1H NMR (400 MHz, CDCl3) δ 1.07 (d, J = 6.5, 6H), 1.25 (s, 9H), 1.34 (t, 
J = 7.1 Hz, 3H), 1.59 (s, 9H), 1.89−2.00 (m, 1H), 2.07 (dd, J = 14.8, 7.3 Hz, 1H), 2.28 (dd, J = 13.0, 
13.0 Hz, 1H), 2.28 (dd, J = 14.8, 3.9 Hz, 1H), 2.37 (dd, J = 13.0, 6.3 Hz, 1H), 2.78 (dd, J = 9.2, 7.5 Hz, 
1H), 3.02−3.12 (m, 1H), 3.06 (s, 3H), 3.16 (dd, J = 9.2, 5.4 Hz, 1H), 3.58 (s, 3H), 4.26−4.41 (m, 2H), 
5.59 (d, J = 8.7 Hz, 1H), 6.37 (d, J = 1.7 Hz, 1H), 6.64 (dd, J = 7.9, 1.7 Hz, 1H), 7.09 (d, J = 7.9 Hz, 
1H), 8.04 (d, J = 0.7 Hz, 1H); 13C-APT{1H} NMR (100 MHz, CDCl 3) δ 14.5, 24.6, 25.3, 25.6, 28.3, 
29.5, 34.9, 37.6, 42.5, 42.7, 54.9, 59.0, 61.5, 64.0, 71.1, 71.8, 82.2, 109.3, 117.3, 126.5, 128.4, 135.4, 
139.6,  146.0,  158.2,  161.2,  169.6,  171.0,  172.3;  HRMS(ESI+)  m/z  [M+H]+  calcd  for  C33H49N2O7S 
617.3255, found 617.3272. 
 
4.1.15. (2S,4S,5R)-1-(4-(tert-Butyl)-3-methoxybenzoyl)-5-(4-(ethoxycarbonyl)thiazol-2-yl)-2-isobutyl-
4-(methoxymethyl)pyrrolidine-2-carboxylic acid (13) 
To a solution of compound 12 (30.8 mg, 0.05 mmol) in dichloromethane (0.6 mL) at 0 ºC was added 
trifluoroacetic acid (0.2 mL) and the resulting solution was stirred at 0 ºC for 14 hours. The reaction 
mixture  was  diluted  with  dichloromethane  (15  mL),  neutralised  with  saturated  aqueous  sodium 
hydrogen carbonate solution and carefully acidified at pH 1 with 1M hydrochloric acid. The organic 
layer  was  separated  and  the  aqueous  layer  was  extracted  with  dichloromethane  (2  x  10  mL).  The 
combined organic extracts were washed with water (10 mL), dried over anhydrous MgSO 4, filtered and 
evaporated under reduced pressure to give compound 13 (26.5 mg, 95% yield) as a brown solid. M.p. = 
55 ºC; [ α]D24 = 61.89 (c = 0.64 in CHCl 3); IR (nujol) 3500−2400, 1741, 1653, 1607, 1565 cm –1; 1H 
NMR (400 MHz, CDCl3) δ 1.09 (d, J = 6.6 Hz, 3H), 1.12 (d, J = 6.6 Hz, 3H); 1.28 (s, 9H), 1.45 (t, J = 
7.1 Hz, 3H), 1.90−2.00 (m, 1H), 2.17−2.23 (m, 2H), 2.30 (dd, J = 15.0, 4.0 Hz, 1H), 2.40 (dd, J = 15.0, 
8.1 Hz, 1H), 2.54 (dd, J = 10.3, 9.4 Hz, 1H), 3.11 (s, 3H), 3.17−3.30 (m, 1H), 3.33 (dd, J = 9.4, 4.5 Hz, 
1H), 3.56 (s, 3H), 4.44 (q, J = 7.1 Hz, 2H), 5.50 (d, J = 8.1 Hz, 1H), 6.31 (d, J = 1.7 Hz, 1H), 6.61 (dd, 
J = 7.9, 1.7 Hz, 1H), 7.12 (d, J = 7.9 Hz, 1H), 8.06 (s, 1H); 13C-APT{1H} NMR (100 MHz, CDCl 3) δ 
14.4,  24.2,  24.9,  25.7,  29.6,  35.0,  35.6,  42.6,  43.5,  55.0,  58.9,  62.4,  64.0,  70.8,  71.3,  109.1,  116.7, 
126.6, 128.3, 135.0, 140.2, 145.9, 158.6, 160.4, 169.9, 172.0, 173.6; HRMS(ESI +) m/z [M+Na] + calcd 
for C29H40N2NaO7S 583.2449, found 583.2441. 
 
4.1.16. tert-Butyl (2S,4S,5S)-1-(4-(tert-butyl)-3-methoxybenzoyl)-2-isobutyl-4-(methoxymethyl)-5-
(thiazol-2-yl)pyrrolidine-2-carboxylate (14) 
To a solution of thioamide 10 (156.2 mg, 0.3 mmol) and bromoacetaldehyde diethyl acetal (295.6 mg, 
1.5 mmol) in dry THF (12 mL) was added HCl/dioxane (4N, 0,1 mL) and the mixture was stirred at 65 
ºC for 24 hours. The reaction mixture was concentrated under reduced pressure and the residue was 
purified by flash chromatography (eluent: diethyl ether/hexane, 1/1) to afford compound 14 (83.3 mg, 
51% yield) as an oil. [α]D24 = −28.67 (c = 0.99 in CHCl3); IR (neat) 3082, 1734, 1652, 1610, 1566 cm–1; 
1H NMR (400 MHz, CDCl 3) δ 1.05 (d, J = 6.3 Hz, 3H), 1.07 (d, J = 6.4 Hz, 3H), 1.28 (s, 9H), 1.51 (s, 
9H), 2.02−2.11 (m, 2H), 2.20 (dd, J = 12.9, 10.7 Hz, 1H), 2.39−2.49 (m, 2H), 2.75−2.86 (m, 1H), 3.28 
(s, 3H), 3.34 (dd, J = 9.6, 6.4 Hz, 1H), 3.47 (dd, J = 9.6, 5.2 Hz, 1H), 3.63 (s, 3H), 5.16 (d, J = 8.3 Hz, 
1H), 6.43 (d, J = 1.7 Hz, 1H), 6.76 (dd, J = 7.9, 1.7 Hz, 1H), 7.06 (d, J = 3.2 Hz, 1H), 7.10 (d, J = 7.9 
Hz, 1H), 7.42 (d, J = 3.2 Hz, 1H); 13C-APT{1H} NMR (100 MHz, CDCl 3) δ 25.4, 25.4, 25.5, 28.1, 
29.6, 34.9, 38.2, 44.1, 47.4, 54.9, 59.1, 64.8, 71.6, 72.3, 81.5, 109.6, 117.6, 119.2, 126.4, 135.9, 139.3, 
142.1, 158.4, 170.4, 172.0, 172.3; HRMS(ESI +) m/z [M+H] + calcd for C 30H45N2O5S 545.3044, found 
545.3056. 
 4.1.17. (2S,4S,5S)-1-(4-(tert-Butyl)-3-methoxybenzoyl)-2-isobutyl-4-(methoxymethyl)-5-(thiazol-2-
yl)pyrrolidine-2-carboxylic acid (15) 
To a solution of compound 14 (27.2 mg, 0.05 mmol) in dichloromethane (0.6 mL) at 0 ºC was added 
trifluoroacetic acid (0.2 mL) and the resulting solution was stirred at 0 ºC for 14 hours. The reaction 
mixture  was  diluted  with  dichloromethane  (15  mL),  neutralised  with  saturated  aqueous  sodium 
hydrogen carbonate solution and carefully acidified at pH 1 with 1M hydrochloric acid. The organic 
layer  was  separated  and  the  aqueous  layer  was  extracted  with  dichloromethane  (2  x  10  mL).  The 
combined  organic  extracts  washed  with  water  (10  mL),  dried  over  anhydrous  MgSO4,  filtered  and 
evaporated under reduced pressure to give compound 15 (23.5 mg, 96% yield) as a brown oil. [ α]D24 = 
−52.63 (c = 0.90 in CHCl 3); IR (neat) 3500−2400, 1728, 1650, 1607, 1566, 1501 cm –1; 1H NMR (400 
MHz, CDCl3) δ 1.03 (d, J = 6.6 Hz, 3H), 1.04 (d, J = 6.6 Hz, 3H), 1.29 (s, 9H), 1.79−1.91 (m, 1H), 
2.20 (dd, J = 14.0, 6.2 Hz, 1H), 2.42 (dd, J = 13.2, 7.2 Hz, 1H), 2.48−2.58 (m, 1H), 2.83 (dd, J = 13.2, 
3.5 Hz, 1H), 2.87 (dd, J = 14.0, 5.8 Hz, 1H); 3.33 (s, 3H), 3.34 (dd, J = 9.8, 8.3 Hz, 1H), 3.42 (dd, J = 
9.8, 5.1 Hz, 1H), 3.61 (s, 3H), 5.26 (d, J = 3.3 Hz, 1H), 6.38 (d, J = 1.6 Hz, 1H), 6.63 (dd, J = 7.9, 1.6 
Hz, 1H), 7.13 (d, J = 7.9 Hz, 1H), 7.15 (d, J = 3.3 Hz, 1H), 7.60 (d, J = 3.3 Hz, 1H), 8.51 (bs, 1H);  13C-
APT{1H} NMR (100 MHz, CDCl 3) δ 24.0, 24.8, 25.2, 29.5, 35.0, 36.6, 43.8, 46.0, 55.0, 59.1, 65.6, 
72.8, 74.5, 108.8, 117.3, 119.6, 126.7, 135.0, 140.1, 142.3, 158.3, 170.9, 173.9, 174.6; HRMS(ESI +) 
m/z [M+Na]+ C26H36N2NaO5S 511.2238, found 511.2251. 
 
4.1.18. (2S,4S,5R)-1-(4-(tert-butyl)-3-methoxybenzoyl)-5-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-
isobutyl-4-(methoxymethyl)pyrrolidine-2-carboxylic acid (16) 
A solution of compound 5 (112.4 mg, 0.2 mmol) in 10% KOH/methanol (5 mL) was refluxed for 5 
days.    The  resulting  mixture  was  cooled  and  the  solvent  evaporated  under  reduced  pressure.  The 
residue was diluted in water (10 mL) and washed with dichloromethane (5 mL). The aqueous layer was 
then  acidified  with  1M  hydrochloric  acid  and  extracted  with  dichloromethane  (2  x  20  mL).  The 
combined organic extracts were dried over anhydrous MgSO 4, filtered and concentrated under reduced 
pressure  to  provide  compound  16  (100.1  mg,  99%  yield)  as  a  white  solid.  M.p.  =  155  ºC;  [α]D24  = 
−99.59  (c  =  1.11  in  CHCl3);  IR  (nujol)  3400−2200,  1739,  1605,  1558  cm–1; 1H  NMR  (400  MHz, 
CDCl3) δ 0.96 (d, J = 6.4 Hz, 3H), 0.98 (d, J = 6.3 Hz, 3H), 1.15 (s, 3H), 1.22 (s, 3H), 1.34 (s, 9H), 
1.73−1.85 (m, 2H), 2.18 (dd, J = 12.6, 6.5 Hz, 1H), 2.36 (dd, J = 15.4, 7.7 Hz, 1H), 2.70−2.82 (m, 1H), 
2.82 (dd, J = 12.6, 12.6 Hz, 1H), 3.24 (dd, J = 9.6, 9.6 Hz, 1H), 3.29 (s, 3H), 3.38 (dd, J = 8.0, 8.0 Hz, 
1H), 3.46 (dd, J = 9.6, 4.4 Hz, 1H), 3.67 (dd, J = 8.0, 6.0 Hz, 1H), 3.35 (s, 3H), 3.88−3.95 (m, 1H), 
4.49 (dd, J = 6.2, 6.2 Hz, 1H), 6.91 (dd, J = 7.9, 1.7 Hz, 1H), 7.04 (bs, 1H), 7.26 (d, J =7.9 Hz, 1H);  
13C-APT{1H} NMR (100 MHz, CDCl3) δ 23.9, 24.7, 24.9, 25.1, 25.9, 29.5, 35.3, 35.8, 39.2, 42.7, 55.2, 
59.0,  65.1,  66.3,  71.2,  73.0,  73.7,  109.1,  112.1,  119.3,  126.7,  134.1,  142.5,  150.0,  174.0,  175.4; 
HRMS(ESI+) m/z [M+Na]+ calcd for C28H43NNaO7 528.2932, found 528.2919. 
 
4.1.19.  tert-Butyl  (2S,4S,5R)-1-(4-(tert-butyl)-3-methoxybenzoyl)-2-isobutyl-4-(methoxymethyl)-5-((S)-
2-oxo-1,3-dioxolan-4-yl)pyrrolidine-2-carboxylate (17) 
To a solution of compound 6 (104.3 mg, 0.2 mmol) in THF (5 mL) was added 1,1’-
carbonyldiimidazole (97.3 mg, 0.6 mmol) and the mixture was stirred at 60 ºC for 24 hours. After that, 
the solvent was evaporated under reduced pressure and the residue was purified by flash 
chromatography (eluent: diethyl ether/hexane, 3/1) to afford compound 17 (98.5 mg, 90% yield) as a 
white solid. M.p. = 90 ºC; [α]D24 = −37.76 (c = 1.01 in CHCl3); IR (nujol) 1815, 1729, 1639, 1565 cm–1; 
1H NMR (400 MHz, CDCl 3) δ 0.93−1.00 (m, 3H), 1.03 (d, J = 6.6 Hz, 3H), 1.34 (s, 9H), 1.52 (s, 9H), 
1.76−1.90  (m,  1H),  1.91−2.05  (m,  1H),  2.10−2.22  (m,  2H),  2.28−2.42  (m,  1H),  2.86−3.02  (m,  1H), 
3.15−3.26  (m,  1H),  3.29  (s,  3H),  3.46  (dd,  J  =  10.2,  4.0  Hz,  1H),  3.88  (s,  3H);  4.03−4.15  (m,  1H), 
4.20−4.31 (m, 1H), 4.55−4.68 (m, 1H), 4.84−4.95 (m, 1H), 6.84 (bd, J = 7.9 Hz, 1H), 7.08 (d, J = 1.7 
Hz, 1H), 7.17 (d, J = 7.9 Hz, 1H); 13C{1H} NMR (100 MHz, CDCl 3) δ 24.4, 25.2, 25.6, 28.1, 29.6, 
35.0, 36.5, 40.8, 41.7, 55.1, 59.1, 63.6, 67.3, 69.3, 70.3, 75.7, 77.4, 82.1, 112.4, 117.8, 125.8, 135.8, 
140.4,  153.4,  159.1,  170.5,  173.1;  HRMS(ESI+)  m/z  [M+H]+  calcd  for  C30H46NO8  548.3218,  found 
548.3232. 
 
4.1.20.  (2S,4S,5R)-1-(4-(tert-Butyl)-3-methoxybenzoyl)-2-isobutyl-4-(methoxymethyl)-5-((S)-2-oxo-1,3-
dioxolan-4-yl)pyrrolidine-2-carboxylic acid (18) 
To a solution of compound 17 (54.7 mg, 0.1 mmol) in dichloromethane (1.2 mL) at 0 ºC was added 
trifluoroacetic acid (0.4 mL) and the resulting solution was stirred at 0 ºC for 14 hours. The reaction 
mixture  was  diluted  with  dichloromethane  (15  mL),  neutralised  with  saturated  aqueous  sodium 
hydrogen carbonate solution and carefully acidified at pH 1 with 1M hydrochloric acid. The organic 
layer  was  separated  and  the  aqueous  layer  was  extracted  with  dichloromethane  (2  x  15  mL).  The 
combined  organic  extracts  washed  with  water  (10  mL),  dried  over  anhydrous  MgSO4,  filtered  and 
evaporated under reduced pressure to give compound 18 (46.1 mg, 94% yield) as a brown solid. M.p. = 
194 ºC; [ α]D24 = −146.28 (c = 0.92 in CHCl 3); IR (nujol) 3700−2500, 1818, 1691, 1653, 1608, 1572 
cm–1; 1H NMR (400 MHz, CDCl 3) δ 1.00 (d, J = 6.7 Hz, 3H), 1.02 (d, J = 6.7 Hz, 3H), 1.36 (s, 9H), 
1.76−1.85 (m, 2H), 2.25 (dd, J = 13.9, 7.8 Hz, 1H), 2.41−2.52 (m, 1H), 2.72−2.84 (m, 1H), 2.98 (dd, J 
= 13.9, 13.9 Hz, 1H), 3.18 (dd, J = 10.5, 7.8 Hz, 1H), 3.28 (s, 3H), 3.52 (dd, J = 10.5, 3.5 Hz, 1H), 3.89 
(s, 3H), 3.95 (dd, J = 9.2, 5.8 Hz, 1H), 4.32 (dd, J = 9.2, 8.0 Hz, 1H), 4.45 (dd, J = 9.9, 6.2 Hz, 1H), 
4.58 (ddd, J = 9.9, 8.0, 5.8 Hz, 1H), 6.79 (dd, J = 7.9, 1.7 Hz, 1H), 7.10 (d, J = 1.7 Hz, 1H), 7.26 (d, J = 
7.9 Hz, 1H); 13C{1H} NMR (100 MHz, CDCl 3) δ 23.8, 24.7, 25.1, 29.5, 34.7, 35.5, 39.1, 42.6, 55.3, 
59.1,  66.3,  67.0,  69.7,  71.9,  74.1,  112.0,  117.6,  126.6,  133.7,  142.3,  153.1,  159.5,  173.8,  176.1; 
HRMS(ESI+) m/z [M+Na]+ calcd for calcd for C26H37NNaO8 514.2412, found 514.2425. 
 
4.1.21. (2S,4S,5R)-1-(4-(tert-Butyl)-3-methoxybenzoyl)-5-carbamoyl-2-isobutyl-4-
(methoxymethyl)pyrrolidine-2-carboxylic acid (19) 
To a solution of compound 8 (50.4 mg, 0.1 mmol) in dichloromethane (1.2 mL) at 0 ºC was added 
trifluoroacetic acid (0.4 mL) and the resulting solution was stirred at 0 ºC for 8 hours. The reaction 
mixture  was  diluted  with  dichloromethane  (15  mL),  neutralised  with  saturated  aqueous  sodium 
hydrogen carbonate solution and carefully acidified at pH 1 with 1M hydrochloric acid. The organic 
layer  was  separated  and  the  aqueous  layer  was  extracted  with  dichloromethane  (2  x  20  mL).  The 
combined organic extracts were washed with water (10 mL), dried over anhydrous MgSO 4, filtered and 
evaporated  under  reduced  pressure  to  give  compound  19  (43.1  mg,  96%  yield)  as  a  brownish  solid. 
M.p. = 253 ºC; [α]D24 = 7.12 (c = 1.01 in CHCl3); IR (nujol) 3600−2200, 3433, 3337, 3209, 1720, 1650, 
1608, 1570 cm–1; 1H NMR (400 MHz, CDCl3) δ 1.01 (d, J = 6.7 Hz, 3H), 1.01 (d, J = 6.7 Hz, 3H), 1.31 
(s, 9H), 1.75−1.89 (m, 1H), 2.01 (dd, J = 13.4, 13.4 Hz, 1H), 2.16 (dd, J = 15.1, 3.6 Hz, 1H), 2.20 (dd, 
J = 13.4, 6.7 Hz, 1H), 2.34 (dd, J = 15.1, 8.3 Hz, 1H), 2.94−3.14 (m, 1H), 3.28 (s, 3H), 3.31−3.40 (m, 
2H), 3.77 (s, 3H), 4.64 (d, J = 8.5 Hz, 1H), 6.45 (bs, 1H), 6.80−6.84 (m, 2H), 7.05 (bs, 1H), 7.22 (d, J = 
8.0 Hz, 1H);  13C-APT{1H} NMR (100 MHz, CDCl 3) δ 23.9, 24.6, 25.7, 29.6, 35.1, 37.0, 41.5, 41.9, 
55.2, 59.1, 65.4, 70.6, 71.5, 109.8, 117.6, 126.8, 134.3, 140.6, 158.7, 170.4, 175.4, 175.4; HRMS(ESI +) 
m/z [M+Na]+ calcd for calcd for C24H36N2NaO6 471.2466, found 471.2481. 
 
4.1.22. tert-Butyl (2S,4S,5R)-1-(4-(tert-butyl)-3-methoxybenzoyl)-2-isobutyl-4,5-
bis(methoxymethyl)pyrrolidine-2-carboxylate (20) 
A  solution  of  compound  7  (97.9  mg,  0.2  mmol)  in  ethanol  (2  mL)  was  reacted  with  sodium 
borohydride  (75.7  mg,  2  mmol)  for  16  hours  at  room  temperature.  The  reaction  was  quenched  with 
saturated aqueous ammonium chloride solution (2 mL) and concentrated under reduced pressure. The 
residue was partitioned between dichloromethane (20 mL) and water (10 mL), the organic layer was 
separated and the aqueous layer extracted with dichloromethane (2 x 10 mL). The combined organic 
extracts were dried over anhydrous MgSO 4, filtered and evaporated under reduced pressure to afford a 
residue  containing  the  crude  alcohol.  To  a  stirred  solution  of  the  crude  alcohol  in  dry  THF  (5  mL) 
under  argon  at  0  ºC  KOtBu  (44.9  mg,  0.4  mmol)  was  added  and  the  mixture  was  stirred  at  room 
temperature for 15 min. Then, iodomethane (172 mg, 1.0 mmol) was added and the slurry was stirred 
for 18 hours at room temperature.  The resulting reaction mixture was quenched with saturated aqueous 
NH4Cl solution (10 mL) and the organic solvent was evaporated under reduced pressure. The aqueous 
layer was extracted with dichloromethane (3 x 20 mL) and the combined organic extracts were dried 
over  anhydrous  MgSO4,  filtered  and  concentrated  under  reduced  pressure.  The  crude  product  was 
purified by flash chromatography (eluent: diethyl ether/hexane, 1/1) to provide compound 20 (85.9 mg, 
85% yield) as a white solid. M.p. = 157 ºC; [ α]D24 = 29.15 (c = 1.04 in CHCl 3); IR (nujol) 1727, 1620, 
1566 cm–1; 1H NMR (400 MHz, CDCl 3) δ 1.00 (d, J = 6.6 Hz, 3H), 1.03 (d, J = 6.6 Hz, 3H), 1.33 (s, 
9H), 1.50 (s, 9H), 1.78−1.89 (m, 1H), 1.91 (dd, J = 13.0, 13.0 Hz, 1H), 1.99 (dd, J = 14.8, 3.6 Hz, 1H), 
2.22 (dd, J = 13.0, 6.8 Hz, 1H), 2.30 (dd, J = 14.8, 8.2 Hz, 1H), 2.78−2.91 (m, 1H), 2.85 (s, 3H), 3.09 
(dd, J = 10.8, 2.8 Hz, 1H), 3.25 (dd, J = 9.5, 7.7 Hz, 1H), 3.31 (s, 1H), 3.52 (dd, J = 9.5, 6.2 Hz, 1H), 
3.60 (dd, J = 10.8, 9.8 Hz, 1H), 3.84 (s, 3H), 4.32 (ddd, J = 9.8, 7.0, 2.8 Hz, 1H), 6.93 (d, J = 1.7 Hz, 
1H), 6.96 (dd, J = 7.9, 1.7 Hz, 1H), 7.25 (d, J = 7.9 Hz, 1H); 13C-APT{1H} NMR (100 MHz, CDCl 3) δ 
24.1, 24.5, 25.8, 28.1, 29.7, 35.0, 38.0, 41.4, 41.7, 55.2, 57.9, 59.0, 60.2, 69.4, 72.0, 72.1, 81.1, 110.4, 
118.4,  126.5,  136.0,  140.3,  158.6,  169.2,  173.3;  HRMS(ESI +)  m/z  [M+H] +  calcd  for  C 29H48NO6 
506.3477, found 506.3488. 
 
4.1.23. (2S,4S,5R)-1-(4-(tert-Butyl)-3-methoxybenzoyl)-2-isobutyl-4,5-bis(methoxymethyl)pyrrolidine-
2-carboxylic acid (21) 
To a solution of compound 20 (50.5 mg, 0.1 mmol) in dichloromethane (1.2 mL) at 0 ºC was added 
trifluoroacetic acid (0.4 mL) and the resulting solution was stirred at 0 ºC for 14 hours. The reaction 
mixture  was  diluted  with  dichloromethane  (15  mL),  neutralised  with  saturated  aqueous  sodium 
hydrogen carbonate solution and carefully acidified at pH 1 with 1M hydrochloric acid. The organic 
layer  was  separated  and  the  aqueous  layer  was  extracted  with  dichloromethane  (2  x  20  mL).  The 
combined organic extracts were washed with water (10 mL), dried over anhydrous MgSO 4, filtered and 
evaporated under reduced pressure to give compound 21 (44.0 mg, 98% yield) as a brown oil. [ α]D24 = 
−53.18 (c = 1.00 in CHCl 3); IR (neat) 3400−2400, 1734, 1636, 1608, 1558 cm –1; 1H NMR (400 MHz, 
CDCl3) δ 1.01 (d, J = 6.7 Hz, 3H), 1.02 (d, J = 6.6 Hz, 3H), 1.36 (s, 9H), 1.75−1.89 (m, 1H), 2.00 (dd, 
J = 14.2, 6.1 Hz, 1H), 2.19 (dd, J = 13.4, 8.0 Hz, 1H), 2.29 (dd, J = 14.2, 5.5 Hz, 1H), 2.59 (dd, J = 
13.4, 13.4 Hz, 1H), 2.72−2.85 (m, 1H), 3.18 (dd, J = 10.2, 4.5 Hz, 1H), 3.21 (s, 3H), 3.25 (dd, J = 10.2, 
4.5 Hz, 1H), 3.31 (s, 3H), 3.31 (dd, J = 9.5, 9.5 Hz 1H), 3.42 (dd, J = 9.5, 5.5 Hz, 1H), 3.85 (s, 3H), 
4.42 (ddd, J = 7.6, 4.5, 4.5 Hz, 1H), 6.91 (dd, J = 8.0, 1.7 Hz, 1H), 6.96 (d, J = 1.7 Hz, 1H), 7.27 (d, J = 
8.0 Hz, 1H); 13C-APT{1H} NMR (100 MHz, CDCl 3) δ 24.5, 24.6, 24.9, 29.6, 35.2, 36.7, 39.2, 42.5, 
55.4,  59.1,  59.2,  63.1,  71.4,  71.9,  72.6,  110.9,  118.5,  126.8,  134.6,  141.6,  159.0,  173.8,  174.2; 
HRMS(ESI+) m/z [M+Na]+ calcd for C25H39NNaO6 472.2670, found 472.2687. 
 
4.1.24. 2-(tert-Butyl) 5-methyl (2S,4S,5R)-1-(4-(tert-butyl)-3-methoxybenzoyl)-2-isobutyl-4-
(methoxymethyl)pyrrolidine-2,5-dicarboxylate (22) 
A solution of compound 7 (97.9 mg, 0.2 mmol) in tert-butanol (8 mL) was diluted with an aqueous 
1.25  M  sodium  phosphate  buffer  (2  mL)  and  the  resulting  mixture  at  room  temperature  was  treated 
with an aqueous 1M potassium permanganate solution (1.2 mL, 1.2 mmol) and vigorously stirred for 2 
hours. Then, saturated aqueous sodium sulfite solution (4 m<l) was added and the pH of the mixture 
was adjusted to 3 with 1M hydrochloric acid. The reaction mixture was diluted with diethyl ether (20 
mL) and the organic layer was separated. The aqueous layer was extracted with diethyl ether (2 x 20 
mL)  and  the  combined  organic  extracts  were  dried  over  anhydrous  MgSO4,  filtered  and  evaporated 
under reduced pressure to afford a residue containing the crude acid. A stirred solution of the resulting 
crude  acid  in  methanol  (5  mL)  was  treated  with  a  2M  solution  of  (trimethylsilyl)diazomethane  in 
diethyl ether at room temperature until yellow color persisted. The reaction mixture was stirred for 1 
hour and then quenched with a few drops of acetic acid until yellow color disappeared. The solvent was 
removed under reduced pressure and the residue was purified by flash chromatography (eluent: diethyl 
ether/hexane, 1/2) to afford compound 22 (92.5 mg, 89% yield) as a white solid. M.p. = 154 ºC; [ α]D24 
= 45.14 (c = 1.01 in CHCl 3); IR (nujol) 1753, 1737, 1720, 1631, 1609, 1567 cm –1; 1H NMR (400 MHz, 
CDCl3) δ 1.00 (d, J = 6.3 Hz, 3H); 1.02 (d, J = 6.3 Hz, 3H), 1.33 (s, 9H), 1.54 (s, 9H), 1.82−1.93 (m, 
1H), 2.07−2.27 (m, 4H), 2.84−2.96 (m, 1H), 3.23 (s, 3H), 3.23−3.29 (m, 2H), 3.37 (s, 3H), 3.80 (s, 
3H), 4.48 (d, J = 8.7 Hz, 1H), 6.73 (d, J = 1.7 Hz, 1H), 6.75 (dd, J = 7.8, 1.7 Hz, 1H), 7.20 (d, J = 7.8 
Hz, 1H); 13C-APT{1H} NMR (100 MHz, CDCl 3) δ 24.4, 24.9, 25.6, 28.1, 29.7, 35.0, 37.6, 41.5, 42.7, 
51.5, 55.1, 59.1, 64.4, 70.6, 71.8, 81.0, 109.5, 117.5, 126.5, 136.0, 139.6, 158.4, 169.2, 170.3, 171.8; 
HRMS(ESI+) m/z [M+H]+ calcd for C29H46NO7 520.3269, found 520.3281. 
 
4.1.25. (2S,4S,5R)-1-(4-(tert-Butyl)-3-methoxybenzoyl)-2-isobutyl-5-(methoxycarbonyl)-4-
(methoxymethyl)pyrrolidine-2-carboxylic acid (23) 
To a solution of compound 22 (52.0 mg, 0.1 mmol) in dichloromethane (1.2 mL) at 0 ºC was added 
trifluoroacetic acid (0.4 mL) and the resulting solution was stirred at 0 ºC for 14 hours. The reaction 
mixture  was  diluted  with  dichloromethane  (15  mL),  neutralised  with  saturated  aqueous  sodium 
hydrogen carbonate solution and carefully acidified at pH 1 with 1M hydrochloric acid. The organic 
layer  was  separated  and  the  aqueous  layer  was  extracted  with  dichloromethane  (2  x  20  mL).  The 
combined organic extracts were washed with water (10 mL), dried over anhydrous MgSO 4, filtered and 
evaporated under reduced pressure to give compound 23 (44.0 mg, 97% yield) as a brown solid. M.p. = 
107 ºC; [α]D24 = −13.35 (c = 1.06 in CHCl 3); IR (nujol) 3500−2400, 1753, 1717, 1628, 1564 cm –1; 1H 
NMR (400 MHz, CDCl 3) δ 1.02 (d, J = 6.6 Hz, 6H), 1.34 (s, 9H), 1.75−1.88 (m, 1H), 2.08 (dd, J = 
14.5, 7.2 Hz, 1H), 2.20 (dd, J = 13.6, 7.0 Hz, 1H), 2.36 (dd, J = 14.5, 4.8 Hz, 1H), 2.57 (dd, J = 13.6, 
11.4 Hz, 1H), 2.77−2.91 (m, 1H), 3.23 (s, 3H), 3.27 (dd, J = 9.9, 6.8 Hz, 1H), 3.33 (dd, J = 9.9, 4.6 Hz, 
1H), 3.54 (s, 3H), 3.81 (s, 3H), 4.64 (d, J = 8.1 Hz, 1H), 6.74−6.8 (m, 2H), 7.25 (d, J = 7.9 Hz, 1H); 
13C-APT{1H} NMR (100 MHz, CDCl3) δ 24.2, 24.8, 24.8, 29.5, 35.2, 36.3, 41.4, 42.3, 52.9, 55.3, 59.1, 
65.5,  70.4,  72.7,  109.8,  117.7,  126.9,  134.0,  141.3,  158.8,  172.5,  173.0,  173.0;  HRMS(ESI+)  m/z 
[M+Na]+ calcd for C25H37NNaO7 486.2463, found 486.2448. 
 
4.1.26. tert-Butyl (2S,4S,5S)-1-(4-(tert-butyl)-3-methoxybenzoyl)-2-isobutyl-4-(methoxymethyl)-5-
vinylpyrrolidine-2-carboxylate (24) 
To a suspension of methyl triphenylphosphonium bromide (428.7 mg, 1.2 mmol) in dry toluene (9 mL) 
at 0 ºC and under argon atmosphere was added potassium tert-butoxide  (112.2 mg, 1.0 mmol) and the 
mixture  was  stirred  at  room  temperature  for  2  hours.  Then,  a  solution  of  aldehyde  7  (98.0  mg,  0.2 
mmol)  in  dry  toluene  (3  mL)  was  added  dropwise  and  the  reaction  was  allowed  to  proceed  for  24 
hours. The reaction was quenched with saturated aqueous ammonium chloride solution (10 mL) and 
extracted  with  ethyl  ether  (2  x  20  mL).  The  combined  organic  extracts  were  dried  over  anhydrous 
MgSO4, filtered and evaporated under reduced pressure and the residue was purified by flash 
chromatography (eluent: diethyl ether/hexane, 1/1) to afford compound 24 (88.6 mg, 91% yield) as a 
white solid. M.p. = 162 ºC; [ α]D24 = −27.86 (c = 0.96 in CHCl 3); IR (nujol) 3076, 1728, 1653, 1610, 
1567 cm–1; 1H NMR (400 MHz, CDCl 3) δ 1.01 (d, J = 6.6 Hz, 3H), 1.05 (d, J = 6.5 Hz, 3H), 1.33 (s, 
9H), 1.52 (s, 9H), 1.82−1.92 (m, 1H), 1.90 (dd, J = 13.1, 13.1 Hz, 1H), 2.04 (dd, J = 14.8, 3.7 Hz, 1H), 
2.15 (dd, J = 13.1, 6.7 Hz, 1H), 2.29 (dd, J = 14.8, 8.2 Hz, 1H), 2.75−2.87 (m, 1H), 3.20 (d, J = 7.1 Hz, 
2H), 3.24 (s, 3H), 3.79 (s, 3H), 4.35 (dd, J = 17.2, 1.6 Hz, 1H), 4.52 (dd, J = 9.4, 8.0 Hz, 1H), 4.79 (dd, 
J = 10.2, 1.6 Hz, 1H), 5.87 (ddd, J = 17.2, 10.2, 9.4 Hz, 1H), 6.77 (d, J = 1.7 Hz, 1H), 6.83 (dd, J = 7.9, 
1.7 Hz, 1H), 7.18 (d, J = 7.9 Hz, 1H), 9.6 Hz, 1H); 6.77 (d, J=1.6 Hz, 1H); 6.83 (dd, J=7.9, 1.6 Hz, 
1H);  7.18  (d,  J=7.9  Hz,  1H); 13C-APT{1H}  NMR  (100  MHz,  CDCl3) δ  24.1,  24.6,  25.8,  28.1,  29.7, 
35.0, 37.9, 41.8, 41.9, 55.2, 59.1, 66.1, 69.8, 72.5, 81.2, 110.5, 117.6, 118.2, 126.0, 134.0, 136.5, 139.7, 
158.2, 169.9, 173.3; HRMS(ESI+) m/z [M+H]+ calcd for C29H46NO5 488.3371, found 488.3370. 
 
4.1.27. tert-Butyl (2S,4S,5S)-1-(4-(tert-butyl)-3-methoxybenzoyl)-5-ethyl-2-isobutyl-4-
(methoxymethyl)pyrrolidine-2-carboxylate (25) 
A solution of compound 24 (48.7 mg, 0.1 mmol) in ethanol (5 mL) was hydrogenated with Pd/C 10% 
(20 mg) as catalyst at room temperature for 12 hours. The catalyst was removed by filtration through a 
short Celite® pad and the filtrate evaporated to dryness to afford compound 25 (45.5 mg, 93% yield) as 
a white solid. M.p. = 152 ºC; [ α]D24 = −8.40 (c = 1.04 in CHCl 3); IR (nujol) 1728, 1621, 1567 cm –1; 1H 
NMR (400 MHz, CDCl3) δ 0.46 (t, J = 7.5 Hz, 3H), 1.00 (d, J = 6.6 Hz, 3H), 1.01 (d, J = 6.6 Hz, 3H), 
1.34 (s, 9H), 1.44−1.58 (m, 2H), 1.49 (s, 9H), 1.78−1.92 (m, 1H), 1.87 (dd, J = 12.7, 12.7 Hz, 2H), 
1.99  (dd,  J  =  15.1,  3.9  Hz,  1H),  2.09  (dd,  J  =  12.7,  6.5  Hz,  1H),  2.31  (dd,  J  =  15.1,  7.7  Hz,  1H), 
2.78−2.91 (m, 1H), 3.29 (s, 3H), 3.26−3.39 (m, 2H), 3.82 (s, 3H), 4.06−4.16 (m, 1H), 6.90−6.95 (m, 
2H), 7.22 (d, J = 8.3 Hz, 1H); 13C-APT{1H} NMR (100 MHz, CDCl 3) δ 11.9, 24.3, 24.5, 25.6, 25.8, 
28.1, 29.7, 35.0, 37.3, 41.6, 42.1, 55.2, 58.9, 63.9, 69.1, 71.8, 80.9, 110.8, 118.6, 126.2, 136.6, 139.9, 
158.5, 169.5, 173.5; HRMS(ESI+) m/z [M+H]+ calcd for C29H48NO5 490.3527, found 490.3540. 
 
4.1.28. (2S,4S,5S)-1-(4-(tert-Butyl)-3-methoxybenzoyl)-5-ethyl-2-isobutyl-4-
(methoxymethyl)pyrrolidine-2-carboxylic acid (26) 
To a solution of compound 25 (24.5 mg, 0.05 mmol) in dichloromethane (0.6 mL) at 0 ºC was added 
trifluoroacetic acid (0.2 mL) and the resulting solution was stirred at 0 ºC for 14 hours. The reaction 
mixture  was  diluted  with  dichloromethane  (15  mL),  neutralised  with  saturated  aqueous  sodium 
hydrogen carbonate solution and carefully acidified at pH 1 with 1M hydrochloric acid. The organic 
layer  was  separated  and  the  aqueous  layer  was  extracted  with  dichloromethane  (2  x  10  mL).  The 
combined organic extracts were washed with water (10 mL), dried over anhydrous MgSO 4, filtered and 
evaporated under reduced pressure to give compound 26 (21.0 mg, 97% yield) as a brown oil. [ α]D24 = 
−106.76 (c = 1.00 in CHCl 3); IR (neat) 3500−2300, 1740, 1635, 1607, 1542 cm –1; 1H NMR (400 MHz, 
CDCl3) δ 0.66 (t, J = 7.4 Hz, 3H), 0.98 (d, J = 6.6 Hz, 3H); 1.00 (d, J = 6.6 Hz, 3H), 1.37 (s, 9H), 
1.30−1.40  (m,  2H),  1.74−1.84  (m,  2H),  2.16−2.26  (m,  1H),  2.40−2.47  (m,  1H),  2.64−2.76  (m,  2H), 
3.31 (s, 3H), 3.31 (dd, J = 9.6, 9.6 Hz, 1H), 3.41 (dd, J = 9.6, 4.8 Hz, 1H), 3.86 (s, 3H), 4.35 (ddd, J = 
10.0, 4.8, 4.8 Hz, 1H), 6.94 (dd, J = 7.9, 1.7 Hz, 1H), 6.98 (d, J = 1.7 Hz, 1H), 7.29 (d, J = 7.9 Hz, 1H); 
13C-APT{1H} NMR (100 MHz, CDCl3) δ 10.8, 22.8, 23.9, 24.7, 25.0, 29.6, 35.3, 35.6, 40.1, 42.4, 55.4, 
59.2,  66.0,  71.7,  72.2,  111.6,  119.5,  126.9,  134.2,  142.3,  159.0,  174.5,  175.0;  HRMS(ESI +)  m/z 
[M+Na]+ calcd for C25H39NNaO5 456.2721, found 456.2741. 
 
4.1.29. tert-Butyl (2S,4S,5R)-5-(acetoxymethyl)-1-(4-(tert-butyl)-3-methoxybenzoyl)-2-isobutyl-4-
(methoxymethyl)pyrrolidine-2-carboxylate (27) 
A  solution  of  compound  7  (97.9  mg,  0.2  mmol)  in  ethanol  (2  mL)  was  reacted  with  sodium 
borohydride  (75.7  mg,  2  mmol)  for  16  hours  at  room  temperature.  The  reaction  was  quenched  with 
saturated aqueous ammonium chloride solution (2 mL) and concentrated under reduced pressure. The 
residue was partitioned between dichloromethane (20 mL) and water (10 mL), the organic layer was 
separated and the aqueous layer extracted with dichloromethane (2 x 10 mL). The combined organic 
extracts were dried over anhydrous MgSO 4, filtered and evaporated under reduced pressure to afford a 
residue containing the crude alcohol. To a stirred solution of the crude alcohol in pyridine (5 mL) was 
successively  added  DMAP  (12.2  mg,  0.1  mmol)  and  acetic  anhydride  (2.04,  20.0  mmol)  and  the 
resulting  mixture  was  stirred  at  room  temperature  for  18  hours.  Then,  the  reaction  mixture  was 
evaporated under reduced pressure and the residue was partitioned between dichloromethane (20 mL) 
and water (10 mL). The organic layer was separated and the aqueous layer extracted with 
dichloromethane  (2  x  10  mL).  The  combined  organic  extracts  were  dried  over  anhydrous  MgSO4, 
filtered and evaporated under reduced pressure.  The crude product was purified by flash 
chromatography (eluent: diethyl ether/hexane, 1/1) to afford compound 27 (103.5 mg, 97% yield) as a 
white solid. M.p. = 79 ºC; [ α]D24 = 14,16 (c = 1.25 in CHCl 3); IR (nujol) 1736, 1622, 1566 cm –1; 1H 
NMR (400 MHz, CDCl3) δ 0.99 (d, J = 6.6 Hz, 3H), 1.00 (d, J = 6.6 Hz, 3H), 1.33 (s, 9H), 1.48 (s, 9H), 
1.75 (s, 3H), 1.77−1.88 (m, 1H), 1.90 (dd, J = 13.2, 13.2 Hz, 1H), 1.99 (dd, J = 14.9, 3.7 Hz, 1H), 2.17 
(dd, J = 13.2, 6.9 Hz, 1H), 2.31 (dd, J = 14.9, 8.1 Hz, 1H), 2.83−2.95 (m, 1H), 3.29 (s, 3H), 3.31 (dd, J 
= 9.5, 6.8 Hz, 1H), 3.38 (dd, J = 9.5, 7.5 Hz, 1H), 3.82 (s, 3H), 3.89 (dd, J = 11.6, 5.2 Hz, 1H), 4.23 
(dd, J = 11.6, 7.3 Hz, 1H), 6.91−6.96 (m, 2H), 7.22 (d, J = 7.8 Hz, 1H); 13C-APT{1H} NMR (100 MHz, 
CDCl3) δ 20.7, 24.2, 24.4, 25.8, 28.0, 29.6, 35.0, 37.3, 41.3, 41.3, 55.1, 59.1, 60.3, 63.5, 69.4, 71.4, 
81.3, 110.7, 118.4, 126.4, 135.8, 140.2, 158.6, 169.4, 170.3, 173.0; HRMS(ESI +) m/z [M+H]+ calcd for 
C30H48NO7 534.3426, found 534.3447. 
 4.1.30. (2S,4S,5R)-5-(Acetoxymethyl)-1-(4-(tert-butyl)-3-methoxybenzoyl)-2-isobutyl-4-
(methoxymethyl)pyrrolidine-2-carboxylic acid (28) 
To a solution of compound 27 (53.4 mg, 0.1 mmol) in dichloromethane (1.2 mL) at 0 ºC was added 
trifluoroacetic acid (0.4 mL) and the resulting solution was stirred at 0 ºC for 6 hours. The reaction 
mixture  was  diluted  with  dichloromethane  (15  mL),  neutralised  with  saturated  aqueous  sodium 
hydrogen carbonate solution and carefully acidified at pH 1 with 1M hydrochloric acid. The organic 
layer  was  separated  and  the  aqueous  layer  was  extracted  with  dichloromethane  (2  x  20  mL).  The 
combined organic extracts were washed with water (10 mL), dried over anhydrous MgSO 4, filtered and 
evaporated under reduced pressure to give compound 28 (46.7 mg, 98% yield) as a brownish oil. [α]D24 
= −72.69 (c = 1.06 in CHCl3); IR (neat) 3700−2200, 1739, 1638, 1609, 1564 cm–1; 1H NMR (400 MHz, 
CDCl3) δ 1.00 (d, J = 6.6 Hz, 3H), 1.00 (d, J = 6.6 Hz, 3H), 1.36 (s, 9H), 1.75−1.86 (m, 1H), 1.88 (dd, 
J = 13.8, 5.6 Hz, 1H), 2.02 (s, 3H), 2.22 (dd, J = 11.6, 5.9 Hz, 1H), 2.36 (dd, J = 13.8, 5.7 Hz, 1H), 
2.67−2.84 (m, 2H), 3.29 (s, 3H), 3.29 (dd, J = 9.6, 9.6 Hz, 1H), 3.48 (dd, J = 9.6, 4.7 Hz, 1H), 3.78 (dd, 
J = 12.2, 3.8 Hz, 1H), 3.86 (s, 3H), 4.06 (dd, J = 12.2, 3.8 Hz, 1H), 4.53 (ddd, J = 7.3, 3.8, 3.8 Hz, 1H), 
6.90 (dd, J = 7.9, 1.7 Hz, 1H), 6.96 (d, J = 1.7 Hz, 1H), 7.29 (d, J = 7.9 Hz, 1H); 13C-APT{1H} NMR 
(100 MHz, CDCl 3) δ 21.0, 24.0, 24.6, 25.0, 29.5, 35.2, 36.6, 38.4, 42.7, 55.3, 59.3, 62.4, 62.8, 71.6, 
74.0,  110.6,  118.2,  127.0,  133.8,  141.9,  159.0,  170.8,  173.9,  174.7;  HRMS(ESI +)  m/z  [M+Na] + 
C26H39NNaO7 500.2619, found 500.2603. 
 
4.1.31. tert-Butyl (2S,4S,5R)-5-((allyloxy)methyl)-1-(4-(tert-butyl)-3-methoxybenzoyl)-2-isobutyl-4-
(methoxymethyl)pyrrolidine-2-carboxylate (29) 
A  solution  of  compound  7  (97.9  mg,  0.2  mmol)  in  ethanol  (2  mL)  was  reacted  with  sodium 
borohydride  (75.7  mg,  2  mmol)  for  16  hours  at  room  temperature.  The  reaction  was  quenched  with 
saturated aqueous ammonium chloride solution (2 mL) and concentrated under reduced pressure. The 
residue was partitioned between dichloromethane (20 mL) and water (10 mL), the organic layer was 
separated  and the aqueous layer extracted with dichloromethane (2 x 10 mL). The combined organic 
extracts were dried over anhydrous MgSO 4, filtered and evaporated under reduced pressure to afford a 
residue  containing  the  crude  alcohol.  To  a  stirred  solution  of  the  crude  alcohol  in  dry  THF  (5  mL) 
under argon at 0 ºC was added sodium hydride (16.0 mg of a 60% dispersion in mineral oil, 0.4 mmol) 
and the mixture was stirred at room temperature for 15 min. Then, allylbromide (173 ml, 242 mg, 2.0 
mmol) was added and the slurry was stirred for 18 hours at room temperature.  The resulting reaction 
mixture  was  quenched  with  saturated  aqueous  NH4Cl  solution  (10  mL)  and  the  organic  solvent  was 
evaporated  under  reduced  pressure.  The  aqueous  phase  was  extracted  with  dichloromethane  (3  x  20 
mL)  and  the  combined  organic  layers  were  dried  over  anhydrous  MgSO4,  filtered  and  concentrated 
under  reduced  pressure.  The  crude  product  was  purified  by  flash  chromatography  (eluent:  diethyl 
ether/hexane, 1/1) to provide compound 29 (101.0 mg, 95% yield) as a white solid. M.p. = 97 ºC; [α]D24 
= 20.90 (c = 1.15 in CHCl 3); IR (nujol) 1725, 1624, 1566 cm –1; 1H NMR (400 MHz, CDCl 3) δ 0.99 (d, 
J = 6.6 Hz, 3H), 1.02 (d, J = 6.5 Hz, 3H), 1.33 (s, 9H), 1.48 (s, 9H), 1.78−1.88 (m, 1H), 1.89 (dd, J = 
13.1, 13.1 Hz, 1H), 1.98 (dd, J = 14.8, 3.5 Hz, 1H), 2.22 (dd, J = 13.1, 6.8 Hz, 1H), 2.29 (dd, J = 14.8, 
8.4 Hz, 1H), 2.79−2.91 (m, 1H), 3.17 (dd, J = 10.9, 2.7 Hz, 1H), 3.27 (dd, J = 9.6, 7.8 Hz, 1H), 3.30 (s, 
3H), 3.35−3.42 (m, 1H), 3.43−3.50 (m, 1H), 3.56 (dd, J = 9.6, 6.3 Hz, 1H), 3.57 (dd, J = 10.9, 10.9 Hz, 
1H), 3.83 (s, 3H), 4.31 (ddd, J = 9.8, 7.0, 2.7 Hz, 1H), 4.90 (ddd, J = 17.2, 3.3, 1.5  Hz, 1H), 4.97 (dq, J 
= 10.4, 2.9, 1.3 Hz, 1H), 5.49 (dddd, J = 17.2, 10.7, 5.4, 5.4 Hz, 1H), 6.90 (d, J = 1.7 Hz, 1H), 6.95 (dd, 
J = 7.9, 1.7 Hz, 1H), 7.25 (d, J = 7.9 Hz, 1H); 13C-APT{1H} NMR (100 MHz, CDCl 3) δ 24.0, 24.4, 
25.8,  28.1,  29.6,  35.0,  38.1,  41.3,  41.7,  55.1,  59.0,  60.7,  69.2,  69.4,  71.1,  72.1,  81.0,  110.4,  116.6, 
118.3, 126.5, 134.5, 135.9, 140.1, 158.6, 169.2, 173.2; HRMS(ESI +) m/z [M+H] + calcd for C 31H50NO6 
532.3633, found 532.3646. 
 
4.1.32. (2S,4S,5R)-5-((Allyloxy)methyl)-1-(4-(tert-butyl)-3-methoxybenzoyl)-2-isobutyl-4-
(methoxymethyl)pyrrolidine-2-carboxylic acid (30) 
To a solution of compound 29 (53.2 mg, 0.1 mmol) in dichloromethane (1.2 mL) at 0 ºC was added 
trifluoroacetic acid (0.4 mL) and the resulting solution was stirred at 0 ºC for 6 hours. The reaction 
mixture  was  diluted  with  dichloromethane  (15  mL),  neutralised  with  saturated  aqueous  sodium 
hydrogen carbonate solution and carefully acidified at pH 1 with 1M hydrochloric acid. The organic 
layer  was  separated  and  the  aqueous  layer  was  extracted  with  dichloromethane  (2  x  20  mL).  The 
combined organic extracts were washed with water (10 mL), dried over anhydrous MgSO 4, filtered and 
evaporated under reduced pressure to give compound 30 (47.1 mg, 99% yield) as a brownish oil. [ α]D24 
= −52.62 (c = 1.05 in CHCl3); IR (neat) 3700−2100, 1739, 1641, 1608, 1550 cm–1; 1H NMR (400 MHz, 
CDCl3) δ 1.00 (d, J = 6.7 Hz, 3H); 1.01 (d, J = 6.6 Hz, 3H), 1.35 (s, 9H), 1.75−1.88 (m, 1H), 1.97 (dd, 
J = 14.2, 6.0 Hz, 1H), 2.20 (dd, J = 13.3, 7.8 Hz, 1H), 2.30 (dd, J = 14.2, 5.6 Hz, 1H), 2.62 (dd, J = 
13.3, 13.3 Hz, 1H), 2.71−2.84 (m, 1H), 3.20−3.28 (m, 2H), 3.30 (s, 3H), 3.32 (dd, J = 9.5, 9.5 Hz, 1H), 
3.42 (dd, J = 9.5, 5.6 Hz, 1H), 3.79−3.83 (m, 2H), 3.84 (s, 3H), 4.45 (ddd, J = 7.4, 4.8, 4.8 Hz, 1H), 
5.12−5.16 (m, 1H), 5.16−5.19 (m, 1H), 5.79 (dddd, J = 17.8, 9.8, 5.9, 5.9 Hz, 1H), 6.90 (dd, J = 7.9, 
1.7 Hz, 1H), 6.95 (d, J = 1.7 Hz, 1H), 7.26 (d, J = 7.9 Hz, 1H); 13C-APT{1H} NMR (100 MHz, CDCl3) 
δ 24.4, 24.6, 24.9, 29.6, 35.2, 36.6, 39.0, 42.5, 55.3, 59.2, 63.2, 68.4, 71.8, 72.5, 72.7, 111.0, 118.3, 
118.4, 126.7, 133.9, 134.6, 141.5, 158.9, 174.0, 174.3; HRMS(ESI+) m/z [M+Na]+ calcd for 
C27H41NNaO6 498.2827, found 498.2841. 
 
4.1.33. tert-Butyl (2S,4S,5R)-1-(4-(tert-butyl)-3-methoxybenzoyl)-2-isobutyl-5-
(((methoxycarbonyl)oxy)methyl)-4-(methoxymethyl)pyrrolidine-2-carboxylate (31) 
A  solution  of  compound  7  (97.9  mg,  0.2  mmol)  in  ethanol  (2  mL)  was  reacted  with  sodium 
borohydride  (75.7  mg,  2  mmol)  for  16  hours  at  room  temperature.  The  reaction  was  quenched  with 
saturated aqueous ammonium chloride solution (2 mL) and concentrated under reduced pressure. The 
residue was partitioned between dichloromethane (20 mL) and water (10 mL), the organic layer was 
separated and the aqueous layer extracted with dichloromethane (2 x 10 mL). The combined organic 
extracts were dried over anhydrous MgSO 4, filtered and evaporated under reduced pressure to afford a 
residue containing the crude alcohol. To a stirred solution of the crude alcohol and DMAP (12.2 mg, 
0.1 mmol) in a mixture of dry dichloromethane (2 mL) and dry pyridine (2 mL) under argon at 0ºC was 
added  dropwise  methyl  chloroformate  (2.32  mL,  30.0  mmol)  and  the  mixture  was  stirred  at  room 
temperature  for  2  hours.  Then,  the  reaction  mixture  was  diluted  with  dichloromethane  (30  mL)  and 
washed  with  water  (2  x  10  mL).  The  organic  layer  was  dried  over  anhydrous  MgSO4,  filtered  and 
concentrated under reduced pressure. The crude product was purified by flash chromatography (eluent: 
diethyl ether/hexane, 1/1) to give compound 31 (105.5 mg, 96% yield) as a white solid. M.p. = 78 ºC; 
[α]D24  =  18.01  (c  =  1.10  in  CHCl3);  IR  (nujol)  1754,  1727,  1614,  1566  cm–1; 1H  NMR  (400  MHz, 
CDCl3) δ 1.00 (d, J = 6.6 Hz, 3H), 1.01 (d, J = 6.6 Hz, 3H), 1.33 (s, 9H), 1.50 (s, 9H), 1.77−1.90 (m, 
1H), 1.96 (dd, J = 13.1, 13.1 Hz, 1H); 1.99 (dd, J = 15.1, 4.0 Hz, 1H), 2.18 (dd, J = 13.1, 6.9 Hz, 1H), 
2.32 (dd, J = 15.1, 7.8 Hz, 1H), 2.82−2.95 (m, 1H), 3.28 (s, 3H), 3.32 (dd, J = 9.6, 6.3 Hz, 1H), 3.40 
(dd, J = 9.6, 7.3 Hz, 1H), 3.60 (s, 3H), 3.83 (s, 3H), 3.94 (dd, J = 11.2, 4.6 Hz, 1H), 4.30 (dd, J = 11.2, 
8.1 Hz, 1H), 4.52 (dd, J = 7.6, 7.6, 4.7 Hz, 1H), 6.90 (dd, J = 7.9, 1.7 Hz, 1H), 6.93 (d, J = 1.7 Hz, 1H), 
7.22 (d, J = 7.9 Hz, 1H); 13C-APT{1H} NMR (100 MHz, CDCl 3) δ 24.3, 24.4, 25.8, 28.0, 29.6, 35.0, 
37.2, 41.3, 41.3, 54.7, 55.0, 59.0, 60.1, 66.5, 69.3, 71.2, 81.4, 110.7, 118.1, 126.4, 135.6, 140.2, 155.1, 
158.6, 169.5, 173.0; HRMS(ESI+) m/z [M+H]+ calcd for C40H48NO8 550.3375, found 550.3393. 
 
4.1.34. (2S,4S,5R)-1-(4-(tert-Butyl)-3-methoxybenzoyl)-2-isobutyl-5-(((methoxycarbonyl)oxy)methyl)-
4-(methoxymethyl)pyrrolidine-2-carboxylic acid (32) 
To a solution of compound 31 (55.0 mg, 0.1 mmol) in dichloromethane (1.2 mL) at 0 ºC was added 
trifluoroacetic acid (0.4 mL) and the resulting solution was stirred at 0 ºC for 6 hours. The reaction 
mixture  was  diluted  with  dichloromethane  (15  mL),  neutralised  with  saturated  aqueous  sodium 
hydrogen carbonate solution and carefully acidified at pH 1 with 1M hydrochloric acid. The organic 
layer  was  separated  and  the  aqueous  layer  was  extracted  with  dichloromethane  (2  x  20  mL).  The 
combined  organic  extracts  washed  with  water  (10  mL),  dried  over  anhydrous  MgSO4,  filtered  and 
evaporated  under  reduced  pressure  to  give  compound  32  (48.4  mg,  98%  yield)  as  a  brownish  solid. 
M.p. = 81 ºC; [α]D24 = −72.29 (c = 1.08 in CHCl 3); IR (nujol) 3700−2300, 1757, 1739, 1638, 1562 cm –
1; 1H  NMR  (400  MHz,  CDCl3) δ  0.99  (d,  J  =  6.6  Hz,  3H),  0.99  (d,  J  =  6.5  Hz,  3H),  1.35  (s,  9H), 
1.73−1.84 (m, 1H), 1.86 (dd, J = 13.8, 5.6 Hz, 1H), 2.24 (dd, J = 12.7, 6.7 Hz, 1H), 2.36 (dd, J = 13.8, 
5.6 Hz, 1H), 2.69 (dd, J = 12.7, 12.7 Hz, 1H), 2.70−2.83 (m, 1H), 3.29 (s, 3H), 3.30 (dd, J = 9.6, 8.6 
Hz, 1H), 3.46 (dd, J = 9.6, 5.0 Hz, 1H), 3.66 (s, 3H), 3.80 (dd, J = 11.7, 6.9 Hz, 1H), 3.86 (s, 3H), 4.16 
(dd, J = 11.7, 4.0 Hz, 1H), 4.55 (ddd, J = 6.9, 6.9, 4.0 Hz, 1H), 6.86 (dd, J = 7.9, 1.7 Hz, 1H), 7.02 (d, J 
= 1.7 Hz, 1H), 7.26 (d, J = 7.9 Hz, 1H); 13C-APT{1H} NMR (100 MHz, CDCl 3) δ 24.0, 24.6, 24.9, 
29.5, 35.2, 36.1, 38.5, 42.5, 55.0, 55.2, 59.2, 62.4, 65.8, 71.1, 73.0, 111.3, 118.0, 126.7, 134.0, 141.6, 
155.2,  158.9,  173.9,  174.9;  HRMS(ESI +)  m/z  [M+Na] +  calcd  for  C 26H39NNaO8  516.2568,  found 
516.2580. 
 
4.1.35. tert-Butyl (2S,4S,5R)-1-(4-(tert-butyl)-3-methoxybenzoyl)-5-(fluoromethyl)-2-isobutyl-4-
(methoxymethyl)pyrrolidine-2-carboxylate (33) 
A  solution  of  compound  7  (97.9  mg,  0.2  mmol)  in  ethanol  (2  mL)  was  reacted  with  sodium 
borohydride  (75.7  mg,  2  mmol)  for  16  hours  at  room  temperature.  The  reaction  was  quenched  with 
saturated aqueous ammonium chloride solution (2 mL) and concentrated under reduced pressure. The 
residue was partitioned between dichloromethane (20 mL) and water (10 mL), the organic layer was 
separated and the aqueous layer extracted with dichloromethane (2 x 10 mL). The combined organic 
extracts were dried over anhydrous MgSO 4, filtered and evaporated under reduced pressure to afford a 
residue containing the crude alcohol. To a stirred solution of the crude alcohol and triethylamine (40.5 
mg, 0.4 mmol) in dry dichloromethane (2 mL) under argon at −20 ºC was added dropwise DAST (53 
ml, 0.4 mmol). After the addition, the reaction mixture was warmed to room temperature and stirred for 
14 hours. Then, the resulting mixture was quenched by adding saturated aqueous NaHCO 3 solution (10 
mL) and extracted with dichloromethane (3 x 20 mL). The combined organic layers were dried over 
anhydrous MgSO4, filtered and concentrated under reduced pressure. The crude product was purified 
by  flash  chromatography  (eluent:  diethyl  ether/hexane,  1/1)  to  afford  compound  33  (51.3  mg,  52% 
yield) as a white solid. M.p. = 136 ºC; [ α]D24 = 7.11 (c = 1.09 in CHCl 3); IR (nujol) 1736, 1622, 1567 
cm–1; 1H NMR (400 MHz, CDCl 3) δ 1.01 (d, J = 6.6 Hz, 3H), 1.03 (d, J = 6.6 Hz, 3H), 1.35 (s, 9H), 
1.50 (s, 9H), 1.80−1.90 (m, 1H), 1.93 (dd, J = 13.1, 13.1 Hz, 1H), 2.00 (dd, J = 14.9, 3.8 Hz, 1H), 2.22 
(dd, J = 13.1, 6.9 Hz, 1H), 2.32 (dd, J = 14.9, 8.1 Hz, 1H), 2.87−2.99 (m, 1H), 3.32 (s, 3H), 3.37 (ddd, 
J = 9.3, 6.9, 1.8 Hz, 1H), 3.50 (ddd, J = 9.3, 7.1, 1.8 Hz, 1H), 3.83 (s, 3H), 4.22 (ddd, J = 45.9, 8.9, 2.9 
Hz, 1H), 4.47 (dd, J = 42.5, 8.3, 8.3 Hz, 1H), 4.43−4.51 (m, 1H), 6.91 (d, J = 1.4 Hz, 1H), 6.94 (dd, J = 
7.9, 1.4 Hz, 1H), 7.25 (d, J = 7.9 Hz, 1H); 13C-APT{1H} NMR (100 MHz, CDCl 3) δ 24.2, 24.4, 25.8, 
28.1, 29.7, 35.1, 37.6, 41.2, 41.4, 55.1, 59.2, 60.7 (d, J = 23.7 Hz), 69.5, 71.6 (d, J = 5.1 Hz), 81.3, 81.6 
(d, J = 174.1 Hz), 110.2, 118.1, 126.7, 135.6, 140.4, 158.7, 169.3, 173.1; HRMS(ESI +) m/z [M+H] + 
calcd for C28H45FNO5 494.3277, found 494.3296. 
 
4.1.36. (2S,4S,5R)-1-(4-(tert-Butyl)-3-methoxybenzoyl)-5-(fluoromethyl)-2-isobutyl-4-
(methoxymethyl)pyrrolidine-2-carboxylic acid (34) 
To a solution of compound 33 (49.4 mg, 0.1 mmol) in dichloromethane (1.2 mL) at 0 ºC was added 
trifluoroacetic acid (0.4 mL) and the resulting solution was stirred at 0 ºC for 6 hours. The reaction 
mixture  was  diluted  with  dichloromethane  (15  mL),  neutralised  with  saturated  aqueous  sodium 
hydrogen carbonate solution and carefully acidified at pH 1 with 1M hydrochloric acid. The organic 
layer  was  separated  and  the  aqueous  layer  was  extracted  with  dichloromethane  (2  x  20  mL).  The 
combined organic extracts were washed with water (10 mL), dried over anhydrous MgSO 4, filtered and 
evaporated under reduced pressure to give compound 34 (43.3 mg, 99% yield) as a brownish oil. [ α]D24 
= −79.74 (c = 1.05 in CHCl3); IR (neat) 3700−2300, 1739, 1711, 1631, 1607, 1564 cm –1; 1H NMR (400 
MHz, CDCl3) δ 1.01 (d, J = 6.5 Hz, 6H), 1.36 (s, 9H), 1.76−1.87 (m, 1H), 1.92 (dd, J = 14.0, 5.8 Hz, 
1H), 2.25 (dd, J = 13.4, 7.7 Hz, 1H), 2.37 (dd, J = 14.0, 5.7 Hz, 1H), 2.66 (dd, J = 13.4, 13.4 Hz, 1H), 
2.72−2.86 (m, 1H), 3.31 (s, 3H); 3.34 (dd, J = 9.6, 9.6 Hz, 1H), 3.47 (dd, J = 9.6, 5.4 Hz, 1H), 3.85 (s, 
3H), 4.27 (dd, J = 47.0, 4.9 Hz, 2H), 4.52 (dddd, J = 21.9, 7.2, 4.9, 4.9 Hz, 1H), 6.89 (dd, J = 7.9, 1.7 
Hz, 1H), 6.94 (d, J = 1.7 Hz, 1H), 7.29 (d, J = 7.9 Hz, 1H); 13C-APT{1H} NMR (100 MHz, CDCl 3) δ 
24.2, 24.6, 24.9, 29.6, 35.2, 36.3, 38.6 (d, J = 1.9 HZ), 42.4, 55.3, 59.2, 63.1 (d, J = 18,5 Hz), 71.3, 
73.0, 82.0 (d, J =174.3 Hz), 110.6, 118.2, 127.0, 134.0, 141.8, 159.1, 174.1, 174.5; HRMS(ESI +) m/z 
[M+Na]+ calcd for C24H36FNNaO5 460.2470, found 460.2485. 
 
 
4.1.37. tert-Butyl (2S,4S,5R)-5-(azidomethyl)-1-(4-(tert-butyl)-3-methoxybenzoyl)-2-isobutyl-4-
(methoxymethyl)pyrrolidine-2-carboxylate (35) 
A  solution  of  compound  7  (195.8  mg,  0.4  mmol)  in  ethanol  (6  mL)  was  reacted  with  sodium 
borohydride (151.4 mg, 4 mmol) for 16 hours at room temperature. The reaction was quenched with 
saturated aqueous ammonium chloride solution (6 mL) and concentrated under reduced pressure. The 
residue was partitioned between dichloromethane (20 mL) and water (10 mL), the organic layer was 
separated and the aqueous layer extracted with dichloromethane (2 x 10 mL). The combined organic 
extracts were dried over anhydrous MgSO 4, filtered and evaporated under reduced pressure to afford a 
residue containing the crude alcohol. To a stirred solution of the crude alcohol and triethylamine (121.5 
mg,  1.2  mmol)  in  dry  dichloromethane  (20  mL)  under  argon  at  0  ºC  was  added  methanesulfonyl 
chloride (93 ml, 1.2 mmol) and the reaction mixture was stirred at 0 ºC for 2 hours. Then the resulting 
mixture was quenched by the addition of a saturated aqueous NaHCO 3 solution (10 mL), the organic 
layer was separated and the aqueous layer extracted with dichloromethane (2 x 10 mL). The combined 
organic exracts were dried over anhydrous MgSO 4, filtered and concentrated under reduced pressure. 
The crude product was used in the next step without further purification. A mixture of crude mesylate, 
NaI (60.0 mg, 0,4 mg) and NaN 3 (260.1 mg, 4.0 mmol) in dry DMF (6 mL) was stirred under argon at 
80 ºC for 14 hours. The solvent was removed at reduced pressure, the residue partitioned between ethyl 
ether  (20  mL)  and  water  (10  mL),  the  organic  layer  separated  and  the  aqueous  layer  extracted  with 
ethyl ether (2 x 20 mL). The combined organic extracts were dried over anhydrous MgSO 4, filtered and 
evaporated under reduced pressure. The crude product was purified by flash chromatography (eluent: 
diethyl ether/hexane, 1/1) to afford compound 35 (200.5 mg, 97% yield) as a white solid. M.p. = 113 
ºC; [α]D24 = 5.73 (c = 1.20 in CHCl 3); IR (nujol) 2104, 1731, 1626, 1566 cm –1; 1H NMR (400 MHz, 
CDCl3) δ 1.00 (d, J = 6.6 Hz, 3H), 1.02 (d, J = 6.5 Hz, 3H), 1.34 (s, 9H), 1.49 (s, 9H), 1.78−1.89 (m, 
1H), 1.88 (dd, J = 13.1, 13.1 Hz, 1H), 1.98 (dd, J = 14.9, 3.7 Hz, 1H), 2.17 (dd, J = 13.1, 6.8 Hz, 1H), 
2.30 (dd, J = 14.9, 8.1 Hz, 1H), 2.83−2.96 (m, 1H), 3.17 (dd, J = 13.0, 9.4 Hz, 1H), 3.25 (dd, J = 13.0, 
3.6 Hz, 1H), 3.31 (s, 3H), 3.33 (dd, J = 9.5, 6.4 Hz, 1H), 3.42 (dd, J = 9.5, 7.3 Hz, 1H), 3.84 (s, 3H), 
4.36−4.44 (m, 1H), 6.93 (d, J = 1.7 Hz, 1H), 6.96 (dd, J = 7.9, 1.7 Hz, 1H), 7.27 (d, J = 7.9 Hz, 1H); 
13C-APT{1H} NMR (100 MHz, CDCl3) δ 24.1, 24.4, 25.8, 28.1, 29.6, 35.1, 37.2, 41.4, 41.6, 51.3, 55.2, 
59.0, 60.9, 69.4, 71.3, 81.4, 110.1, 118.2, 126.7, 135.4, 140.8, 158.8, 169.2, 173.1; HRMS(ESI +) m/z 
[M+H]+ calcd for C28H45N4O5 517.3385, found 517.3401. 
 
 
4.1.38. (2S,4S,5R)-5-(Azidomethyl)-1-(4-(tert-butyl)-3-methoxybenzoyl)-2-isobutyl-4-
(methoxymethyl)pyrrolidine-2-carboxylic acid (36) 
To a solution of compound 35 (51.7 mg, 0.1 mmol) in dichloromethane (1.2 mL) at 0 ºC was added 
trifluoroacetic acid (0.4 mL) and the resulting solution was stirred at 0 ºC for 6 hours. The reaction 
mixture  was  diluted  with  dichloromethane  (15  mL),  neutralised  with  saturated  aqueous  sodium 
hydrogen carbonate solution and carefully acidified at pH 1 with 1M hydrochloric acid. The organic 
layer  was  separated  and  the  aqueous  layer  was  extracted  with  dichloromethane  (2  x  20  mL).  The 
combined organic extracts were washed with water (10 mL), dried over anhydrous MgSO 4, filtered and 
evaporated under reduced pressure to give compound 36 (45.6 mg, 99% yield) as a brownish oil. [ α]D24 
=  −58.82  (c  =  1.00  in  CHCl3);  IR  (neat)  3700−2400,  2102,  1738,  1712,  1639,  1607,  1564  cm–1; 1H 
NMR (400 MHz, CDCl 3) δ 1.00 (d, J = 6.7 Hz, 3H), 1.00 (d, J = 6.6 Hz, 3H), 1.36 (s, 9H), 1.75−1.86 
(m, 1H), 1.92 (dd, J = 14.1, 5.9 Hz, 1H), 2.24 (dd, J = 13.6, 7.6 Hz, 1H), 2.34 (dd, J = 14.1, 5.6 Hz, 
1H), 2.63 (dd, J = 13.6, 13.6 Hz, 1H), 2.73−2.85 (m, 1H), 3.18 (dd, J = 12.9, 7.3 Hz, 1H), 3.24 (dd, J = 
12.9, 5.5 Hz, 1H), 3.28 (dd, J = 9.6, 9.6 Hz, 1H), 3.31 (s, 3H), 3.45 (dd, J = 9.6, 5.3 Hz, 1H), 3.87 (s, 
3H), 4.45−4.52 (m, 1H), 6.91 (dd, J = 7.9, 1.7 Hz, 1H), 7.02 (d, J = 1.7 Hz, 1H), 7.30 (d, J = 7.9 Hz, 
1H); 13C-APT{1H} NMR (100 MHz, CDCl3) δ 24.2, 24.5, 24.9, 29.5, 35.2, 35.8, 39.2, 42.3, 51.0, 55.4, 
59.2,  62.7,  71.1,  72.3,  111.0,  118.5,  126.8,  134.0,  142.0,  159.2,  174.2,  174.7;  HRMS(ESI +)  m/z 
[M+Na]+ calcd for C24H36N4NaO5 483.2577, found 483.2581. 
 
4.1.39. tert-Butyl (2S,4S,5R)-5-(acetamidomethyl)-1-(4-(tert-butyl)-3-methoxybenzoyl)-2-isobutyl-4-
(methoxymethyl)pyrrolidine-2-carboxylate (37) 
A mixture of compound 35 (103.4 mg, 0.2 mmol) and 10% Pd/C (20 mg) in ethyl acetate (5 mL) was 
stirred at room temperature under hydrogen atmosphere for 2 hours. The reaction mixture was filtered 
through a Celite® pad and concentrate under reduced pressure to afford a residue containing the crude 
amine. To a stirred solution of the crude amine in toluene (5 mL) at room temperature was 
subsequently added triethylamine (101.2 mg, 1.0 mmol) and acetic anhydride (102.1 mg, 1.0 mmol) 
and the reaction mixture was stirred at 100 ºC for 4 hours. The reaction was quenched with water (10 
mL) and extracted with dichloromethane (3 x 20 mL). The combined organic extracts were dried over 
anhydrous MgSO4, filtered and evaporated under reduced pressure. The crude product was purified by 
flash chromatography (eluent: diethyl ether) to give compound 37 (69.3 mg, 65% yield) as a colourless 
oil. [α]D24 = 43.81 (c = 1.07 in CHCl 3); IR (nujol) 3304, 1727, 1700, 1678, 1639, 1564 cm –1; 1H NMR 
(400 MHz, CDCl3) δ 1.01 (d, J = 6.6 Hz, 6H), 1.33 (s, 9H), 1.55 (s, 9H), 1.78−1.88 (m, 1H), 1.86 (dd, J 
= 12.8, 12.8 Hz, 1H), 1.89 (s, 3H), 2.01 (dd, J = 14.9, 4.0 Hz, 1H), 2.14 (dd, J = 12.8, 7.2 Hz, 1H), 2.26 
(dd, J = 14.9, 7.1 Hz, 1H), 2.78 (dd, J = 14.8, 3.4 Hz, 1H), 2.84−2.98 (m, 1H), 3.30 (dd, J = 9.3, 9.3 
Hz, 1H), 3.32 (s, 3H); 3.34 (dd, J = 9.3, 6.1 Hz, 1H), 3.54 (ddd, J = 14.8, 8.3, 2.6 Hz, 1H), 3.83 (s, 3H), 
4.36−4.44 (m, 1H), 6.87−6.92 (m, 2H), 7.22 (d, J = 8.5 Hz, 1H), 7.92 (d, J=8.3 Hz, 1H); 13C-APT{1H} 
NMR (100 MHz, CDCl 3) δ 23.2, 24.5, 24.7, 25.7, 28.1, 29.6, 35.0, 38.3, 39.3, 41.1, 42.1, 55.3, 59.2, 
60.7, 70.4, 71.5, 82.7, 110.0, 117.9, 126.6, 135.5, 140.5, 158.8, 169.4, 169.9, 175.4; HRMS(ESI +) m/z 
[M+H]+ calcd for C30H49N2O6 533.3585, found 533.3578. 
 
4.1.40. (2S,4S,5R)-5-(Acetamidomethyl)-1-(4-(tert-butyl)-3-methoxybenzoyl)-2-isobutyl-4-
(methoxymethyl)pyrrolidine-2-carboxylic acid (38) 
To a solution of compound 37 (53.3 mg, 0.1 mmol) in dichloromethane (1.2 mL) at 0 ºC was added 
trifluoroacetic acid (0.4 mL) and the resulting solution was stirred at 0 ºC for 6 hours. The reaction 
mixture  was  diluted  with  dichloromethane  (15  mL),  neutralised  with  saturated  aqueous  sodium 
hydrogen carbonate solution and carefully acidified at pH 1 with 1M hydrochloric acid. The organic 
layer  was  separated  and  the  aqueous  layer  was  extracted  with  dichloromethane  (2  x  20  mL).  The 
combined organic extracts were washed with water (10 mL), dried over anhydrous MgSO 4, filtered and 
evaporated  under  reduced  pressure  to  give  compound  38  (45.3  mg,  95%  yield)  as  a  brownish  solid. 
M.p. = 85 ºC; [ α]D24 = −28.00 (c = 1.02 in CHCl 3); IR (nujol) 3600−2200, 3279, 1730, 1711, 1627, 
1563 cm–1; 1H NMR (400 MHz, CDCl 3) δ 1.00 (d, J = 6.6 Hz, 6H), 1.34 (s, 9H), 1.76−1.88 (m, 1H), 
1.83 (s, 3H), 2.06 (dd, J = 14.4, 6.5 Hz, 1H), 2.21 (dd, J = 13.4, 8.0 Hz, 1H), 2.24 (dd, J = 14.4, 5.0 Hz, 
1H), 2.43 (dd, J = 13.4, 13.4 Hz, 1H), 2.74−2.87 (m, 1H), 3.12 (ddd, J = 14.4, 8.9, 5.6 Hz, 1H), 3.24 
(ddd, J = 14.4, 4.8, 4.8 Hz, 1H), 3.33 (s, 3H), 3.36−3.46 (m, 2H), 3.82 (s, 3H), 4.45−4.52 (m, 1H), 6.82 
(bt, J = 4.8 Hz, 1H), 6.93 (dd, J = 7.9, 1.7 Hz, 1H), 7.06 (d, J = 1.7 Hz, 1H), 7.26 (d, J = 7.9 Hz, 1H); 
13C-APT{1H} NMR (100 MHz, CDCl3) δ 23.2, 24.5, 24.8, 24.8, 29.6, 35.2, 36.8, 39.5, 40.0, 42.1, 55.3, 
59.2, 62.2, 71.0, 71.7, 110.9, 118.2, 126.7, 134.5, 141.3, 158.9, 170.9, 172.5, 176.0; HRMS(ESI +) m/z 
[M+Na]+ calcd for C26H40N2NaO6 499.2779, found 499.2797. 
 
4.2. Biological assays 
4.2.1. Cells and replicon system. 
The highly permissive cell clone Huh /-Lunet, as well as HuH 7 cells containing subgenomic (HCV) 
replicons I389luc-ubi-neo/NS3-3’/5.1 (Huh 5-2), I377NS3-3’/wt (Huh 9-13), or I389/hygro-ubi-NS3-
3’/5.1 (a kind gift from Dr. V. Lohmann and Dr. R. Bartenschaler) has been described [18]. Briefly, 
this  system  allowed  the  efficient  propagation  of  genetically  modified  HCV  RNAs  (replicons)  in  a 
human  hepatoma  cell  line  (Huh).  The  amount  of  RNA  that  has  been  transcribed  and  translated  is 
determined  through  the  quantification  of  a  reporter  contained  the  replicon  system  (luciferase).  The 
amount of luminescence detected (after adding the substrate specific for this enzyme) is proportional to 
the virus replication rate. Cells were grown in a DMEM supplemented with 10% heat-inactivated fetal 
bovine serum 1 x non-essential amino acids, 100 IU/mL penicillin, 100 µg/mL streptomycin and 250 
µg/mL geneticin (G418). 
 
4.2.2. Antiviral and cytostatic assays with Huh 5-2 cells 
Antiviral and cytostatic assays were performed according to the protocol already described in Abian et 
al [19]. The 50% effective concentration (EC50) was defined as the concentration of compound that 
reduced  the  luciferase  signal  by  50  %  and  the  50%  cytotoxic  concentration  (CC50)  was  determined 
employing the dose–response equation (i.e., Hill equation). 
 
4.3.3 Geometry optimization and calculation of molecular descriptors 
Structures of the compounds were optimized at the quantum level with the DFT (Density Functional 
Theory)  functional  b3lyp/6-31+g(d,p)  using  GaussView  5.0.8  and  Gaussian09  [24].  Charge  zero  (0) 
and a multiplicity of one (1) were settled, in the Gaussian input files, for all the compounds. The Homo 
and Lumo energies (in a.u.) of the optimized structures were extracted from the .log Gaussian output 
files, and used to calculate the reactivity (Re) of compounds as: 
𝑅𝑒 ൌ !! ൌ
!
!"#$!!"#" ∗!".!""#
!
ൌ !.!"#$!"#$! !"#"                              (1) 
where, η, is the chemical hardness, and 27.2114 is the conversion rate from a.u. to eV units. 
Thirty-five  additional  molecular  descriptors,  including  steric  ones  (e.g.  molecular  weight,  sum  of 
atomic van der Waals volumes, radius of gyration, molecular eccentricity, spherocity, etc.), 
constitutional ones (e.g. heteroatom percentages, rotatable bond fraction, etc.), ring ones (e.g. 
cyclomatic number, total ring size, aromatic ratio, etc.), molecular properties (e.g. hydrophilic factor, 
molar  refractivity,  octanol-water  partition  coefficient,  etc.)  and  a  consensus  drug-like  score  were 
calculated with the DRAGON 6.0 program [25].  
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Copies of 1H NMR and 13C NMR spectra of all compounds, X-ray crystallographic data (ORTEP) for 
compound 4a (PDF), copies of antiviral activity and cell viability graphs of compounds 13, 15, 16, 18, 
19, 23, 26, 28, 30, 32, 34, 36 and 38, and figures for binding poses of GSK3082 and compounds 13, 
15, 16, 18, 19, 21, 23, 26, 28, 30, 32, 34, 36 and 38. 
X-ray crystallographic data for compound 4a (CIF). 
